Department of Pharmaceuticals, Drugs (Prices Control) Order, 2013
- Kind: Order
- Under: The Essential Commodities Act, 1955
Text of this order
4""
^'o ̂ 0 'iMo-:i.3n04/99
REGD. NO. D. L.-33004/99
■ f.
I I
31RH slit
S^he (Baxette of 3udia
EXTRAORDINARY
’TFT II— 3— (ii)
PART II—Section 3—Sub-section (ii)
yrfsignTwfm
PUBLISHED BY AUTHORITY
■H. 1075]
No. 1075]
^ f^crfr, 15, 2013/%n3-2S, 1935
NEW DELHI, WEDNESDAY, MAY 15, 2013A^AISAKHA 25, 1935
3lk v3^W TraRTO
(3(httf?rtm)
^1^, 15^,2013
‘IjT.3n.122l(3l).— ^IWR, 3il91tiic|7 ^ 3tf?rf^, 1955 (l955 ctn 10) ^[?r ETM 3 gRT
^rf^nfr cpt ft? (g?FRT f^m^) sn^, 1995 ^ gicfr ^ f^grg gR^ fg
^ 3lfllgRM ^ fW W t gr gR^ gg ggr t, 3T1^ gvRft t, 3isrfg : —
■gf&RT gm aJbf Rltn.—(1) 30^ gg gPT STtgftl (gftgg Pragu[) 3n^, 2013 t I
(2) tr ggfgg if HgjRH gif cTT^ git ^ I
gftgrgnj.—(1) 3n^ if gig ggr ^ ̂ aFgag 3iirf$icT g ^,—
(g>) "3ri?tf?tgg" % 3ITggggj g^ 3rf?ff^, 1955 (l955 gg lO) 3iMg t ;
(^) itgfSrcB ^figeqj grufisi sftgfit" % sfrgf^ 3jk iRrm ^Hmift srfSrf^, 1940 (1940 gg 23) ^
3itjtg RRRte giggif ^\3r^ gilt g^mgf^, ^ gt ggpil^ ggng siMg t sratg
FIgg, 3)l^'Hlg't, 3ik cg-dgH ift t 3jk f^iggg g^frg gig if gr fMt if
'H'yecb ^ gig if giRg t ;
(g) "STS" ^ gig, gist, f%gn?g, jRffgi, sggR f^ gr ^ gift 3Fg f^r^mgr siMg t f^Rrir gg?
gff 3ffgfSf g5f R5bOl3ft gff 3flgf^ ^ '{JPt'F gig if gBgRf gif glRft t;
(g) "3tfi|g5clg gffgg" ^ gilt g5fgg 3iMg t gft gRggg i| w 3n^ ^ ^
RPiRfcigl ^ f^ f^gg gif t;
1998 GI/2013
1.
2.
(I)
f,
THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(u)]2
^ ̂ 3lMtl t ̂ TTr-^)Sg>? ̂ aimlM cfj grji tji fUgjij m wi t
3ik sRpfe sifiraKrt ̂ t;
(^) ^ ^ f^cR^i ̂ ̂ ̂ ̂ sif^ siMcT t aft? i?i^ atrptd 'g>rf aiftgKrf in
fcpyft ̂ jcfgr^ cpt ^ 3it^fSrqt gjT ?srg> c^.f^ gft^ yerf^jysr ̂ t;
(T^ "f^R ftPRfdT" ̂ I?I 3TT^ ?iwq^ J)cf,|^H ̂ cpt fltURTT f^lPmtdl 3lf?R!Tr t;
(^) "R?iiq" ̂ jr^t t;
(?f) "RPtPift" ̂ fcfRft g5t ■'d^Rdl ^ TfT \3?TC^ M ^r artdf^ TTT JRim ^
WT Tir ^ ^ ?cf7 ttt 3if?icp afp^Mr ^ f^rai^ ^ cjft afmfSr aifii^RT t
??Rf^ 3i?Rtd PiHfolf^d ^ t, aiSjtcT :—
(i) c^ afPrfgr 3icr>td (fuR# sirnfe ift t) ^ ij?pft (f^) s^mcft ^
^ witI^ 3ik% ift t;
(ii) ■^'1«jl^l(^ H^nctt afmf^ ;
(iii) ^ cptf gfR[f?r 3ft? -mm ?iFnft sTf^rf^m, 1940 (1940 ^ 23) ^ wm ^
i
^ ;
' (oj) sfRflt tUI vflARcjj 'nMmx' ^ i|'Iyft<j ^ T[T fclRft ?lte f^PlRRi it 3raf^
?ra^ ^ ̂ 1?ts[ftcT ^ fSif¥^ arf$i^ ., ■ , . .
(c:) "?i?^' % ?T?^ 3TMd t;
(^ "airam" ^ ??p^ sj|cb#ich ?!iqM aft? yRRttrr ?Ff|d ttrcI ?t?? %?fr ?8TFT ^ fllRft afipf?!
cpi f?t^ c^ 1^ qT?d if eiHT afMrr t;
(5) "?yi4ld tp^" ■^r RPintcii ^ ̂ 3?{^ ail^tcpcrf tp gi?i TR?m f?p??t f!rf^ ^ 3Rft^ ?T?g>i?
TJT yi'J'y yiwiy ^ t%?ft ?8TI%T p|cp|<j ^ ?i^ TR ?f^ (j^<ict5'< cjilHd if ddlK 'ZIT 3TPIRT
Rl^) ^ ̂ TIT ddiJ^ui arMrl t;
(S) ??T an^ MPiPT "f^P^Hldl" ^ ^ ̂^f^ t aft ^ 1^^ :iIT few ^ ̂
afk^if an ftRmW, amiTd tit fclwi ai?dT t;
(w) "dNK- am" ^ Riyfl afipf?! cfr ui^ vff^Rcp yoppR (jiRihh ctif^cp 3ti^ ^ snm? ti^
Tj^ 3ft? ^ -^if^ aft? PT^, TRW cn^ Ti^ epan? if fct^ g5t tj^ ■g?T afipf^ ?T)ft tp
T^ 5m teR^ fct^ c^ ptm pp arjpid siRt^id t;
(d) ^ 3P^ c^ pritapfi c^ "^dcp? Rshcii Tpt Tpf^" ^ i^ecpy Rsltdl dfl ctflp^ pff pf^^icitp
aifiptd t;
(si) "diap? apspRd arirp^' ^ ?rcpt? ^ ?RTi-?m tr ^^ Tpr aftpf?! % ?i^ ?cpRid
aiRrapd tr fcppTi c^ 3iTcp% aiMd t;
(d) arfilchd'H yetpy c^tdd" ^ df aTfStcpcPT cplnd tp ^rgcp? c^tdd app ?aj|-[li( pr 3ft? '^edi, afr rpj
aiPtfid t, Rrt P? aftpRi aiRiP wftppr dfr M arpnft aft? ai^ ^ ^ a? dfwi^ t;
(d) RtRft RRl^ PRI Tf "pRiph Plf^EP 3IT^' ^ PTRR if PRf PRT dp ?TRld RsPri TJfp 3lRptP t,
ai?f a? d?I PRT TPI fctPRT iJeTI pftw appT t 3ft?Tjfeff a^ T^ PTft PRT T^ ddRIpft RtdRI pft ddirp
-t; .
(P) "?T^ 3IITI?TtcP 3itaf& ?PT?S2I 3ft? aRdR PlePTP PdlelP gRT ?1PTI-?TPTI a? 3mdP 3ft?
5p5tRid aft p^ aft? ?R!ad if arfERjapi pthip ^ aapRip ?rpp? ^ ̂ 3p^ aft asia ai^rjEtt if
arf^iRid aft-p^ ?r^ 3pa?acp aftaRi Tjett, 2011 aiRptd t;
(a) i?i 3p^ c^ aTitPRff Rip "tt^ 3ftaf?t" ^ ?p^ spapapi aflaRi ?j^ if yj^ta^ ?na if RiRrf^
aft? pif^ aft aftpRi Rwpr RRrptdi gRi, pp aftaRi aft aftaRr ^ ?p8i fimiPR, pi% p^
TP
apdi
Pldl
3: airaiURni
J •.'
sfraf^r. ̂ ̂f ^ RRRw ̂irsfr crfk gr^ ̂ sfi^ ̂ ^ tit3t ̂ #fr
JfTW 71^ j^PlWRl 3?f5litcr t;
Cp) ^ f^f^Ri t 3irai sfh? wr 3fg^ ^
f; .
(^) "pjnifeilpMfJra^' ̂ ̂ ̂5iiPiq> stM^t t ̂ aiN^r ̂ RiRirHi ^je^i
^ ̂ 3imfir Rif^rHi ̂ ^5^ t;
(3?) "gSkci ^ ̂ 24 3jk 25 ̂r ^ arf^j^ t sft? s^nttr ^5tiT?r ̂
«
t;
(H) "^5eJK c^ cjW" ̂ 1^ 3ft^ ̂ M 3TM?r t ^ ̂ ^5c};7 ^
M ̂ t I^RT^r ^rf^rf^ 13fk ̂«iT%f ̂ ̂rf^ri^ ̂ ̂ f;
(^) c^ira" ̂ ^ lk 5 c^ 3I#T M 3ft^ ̂ ̂ 4?t M 3ff^ t i
(w) "^5ci57 % Tn?g?r ̂ sfl^fM ̂ g>T ^ grar ̂ siggr^ siMct t ;
(^) "3ij<jftd f^PiWRi" ̂ jm 31^^ ̂r 'HPif^d gjtf 3ft f^Ptfificr t ̂
^ ̂ ̂ ^ ̂ f%f^ # ;
(^) "31^^" 3n^ ̂ ̂ai t;
(^itr) "afIcB f^^' ̂ fct># fcl^, 31'WdM, afWgTOT, fxif^ddi, ftrsn ̂ m f^
3F?i 3?firaj^ ̂ sfmfM ̂ f^gj^i H’n c[5t^ cijci^ifl ̂ aff^ra^rf ̂ it t;
' ' (■?T^ "aitcij f^gni ^q;^' ^ ^ 3ik jfRfIr I^itft, ^TRcf ^iwr ^ wi-wj w ^jair
iftf^ ̂ w^sft m aftg> fcm>^r ^fj^r 11.
(2) 5T^ 3ik ^ Tpr 3rfSlf?raiT ^ 3imfSr 3fr? 5RmR WnSt srfSingJT, 1940
(1940 45T 23) ^ uRnif^d ^ 3PI ^ 3ik cfjT ^ 3Taf ^ ^ ^cfvf 3TfSrf%^Ryr t 1
<it<dchi ^n afl^fitqf flftPffM cjt f^mtdisff gjt ftt?i.—^iWR—3.
^ -m aY45%cr if ciiRi^tcR .wfm gft ^ ̂f(i) 3TFTra^>ra’ ^ ̂ ̂f ^
sitwf^nif gft iraf^ vsqeisraT ;fM afk f?rd^ ^ RR^Rd cp^ cfft ^ ̂ f^t?^ 3ft
W4> UT 3jt^ TX\ RPiPfRi ^ 1%^ ra PlHfdl 4ft ^ ̂ frf^ W4) 4T JI^
3Tl4f^ 44 wn44 4ST^ '4ft, 48nf^j1%,f 4ft ^ 3F4 fc|PiRcii3Tt 4>t «r4^
^fWTSft, 3R4cn^ 4T 3ff%^ 4ft ^ ̂ feT? RPififRl 44T% 4Tefr 4ft 1%^ ^ ̂ ^
;
(ii) ^4% (1) ^ 3fEft4 ^ 44t4r4 ^ ^#>4 3^qRjict5 'dkjectff 4T 4^4 aft^f^ 4T
RR(4f[?i4Y ^ RRataiaft ^ ^ ̂ am 4^, 4fr 4? sm^ RRafm, ^ wi
^ 3ft44i 4ft ^14444 Rdd 45^, 3T^f^I4 ^J44T ^41 I
fiti^ RRWQt 4jt 3rf?t44m 4ftim c^t -hmurt. —(i) RRR'c 4if^ afk w 4?t 3m ^
44TRRf^ ^ ^ =
4434 1. 4444:, ^54454 Rs^ ^ RRRIcf 3f4t4 ^ft (w) ^ft 3ftw 4ft44 45t WHT R**iRi[^d
3EW if 45t 4nT33ft :
. 544i4 4ft 3ihra 4>t44, 35t(T?4) = (44 3it4fSr 4^414 4Tf^ 34|xT ^ 34414 44 41444
‘ 34f4 ^ 443 uRijld ■^l 31R43 41 44144 41444 3141 41^ 31t4f^ 4T3ft 41^ 3ft43YffR43 4i4td% 44
^4434 45t 4Wr ^ 4t4) / (^ 3M& ^ ilRm 4lf^ 34^ ^ 34E44 44 ^ 41444 34^ ^
443 4f!ltRl ^ 31^43 41 441^ 44144 4T444 3141 41cft 3114^ ^ ^ 4i^ 3ft4 3^^ 4n4icrfl 45t ^
44154 I )
4.
4 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
2.- 3raI^cI ^ 3ri?icpfiTT ^ ̂fjwrr Rnl^Rdd ̂
:
it(^) = Tjt(xFFr). (1 + TiTr/i 00);.^ tr
= -gm ̂ 1 ^ 3tWir ^ ?if^ atk w ̂ ^ ajk^r *
O<■
^ ̂ JTTf^ ^PT JlfcRRT 3jk ^ = 16
(2) ^ ikl (1) ^ 31^ >EPTlk?T 3lk WPTY gM 3lf?Rjfl|?r 3?1?raiTPT cfW 3R^ aTPHf^ ^ ̂
I
^lk5WT^#T3iTc^^3Tl^g5t3JSg5Yg5kHg5tWTT%4^ gTT^(l)^r^!iaim^M I
(2) (i) gRT Tk^ 4Nk ^r ai^qHSI ^ 3fkf^ c^ ^ 15 3ItfH ^rf f!kn?^ cff[ ^RmJt
^!Tf?rfcr ^ kfipiRijil Xf^ ^ 3f[^ ^ ^ w krro gn unipft i
(ii)W=i£« « ?f^ra .K (i) « Jjif, fiEta liS
^rntyR t%^RT ^ umr^ I
6. ^ cj^ CRI^ ^ ^ ̂ ̂ ̂
^ RY. -kl 4 % (1) it ^ c^
g^tRrr cPT RIM,—
^) ^ g5M5? 1^ cf^r gflM ^ ^ it gn 3tkRi gW ^ Mtt ^
m;3rk
5.
-(1)aig^qfxRT RPiRfd,^ 5jrig7'< tt^nr'cpt 3itMaTTEIR RY
N Rl^ gr 3Tf?fcp giRMsm wt g]k mm c^ fkR Rig rngfcTTatt ^
gt 3lf?tgHTR gJtgg gft ^TRlgRT kpgfkfeg g)R if g^t gnRjft :
R»R krkRtcIT
^ )pc<^'< Tqj^dl W ^rjT'eid ^*lci ^ ’d^iuidl PiHf^Rdd ^ ̂ nijf) ;.
^1 : RgRg:, ^ 31^^ mm 3rgtg -Tft(Rg) gn tlf^ g^t ajk^r g^t^ gst
■giR R g5t RIKpft ; 'ftwn kiHf^fed
= Rl^KitSk gtlHd grkt 3<3vijrgd gtt 'gjggR gfr gttgg
2 ̂ 3fhM R^M g^ kWfT ^ fkR kt Rt 3lteT
- ̂gm^IRfkR)g5t^5gg?RfMRTg^3tkRT^^g^^grrRf%iRn
;?R=3t^ gttkMT i
■ 3T^ f!rf%f5tf^ ^
^(^) =^(RR).(1+IJR/ioo), gl?f TR
■ ^(RR) = ?Rif RiRR gRur 1 if
RR = ^JggR f^sfjcll gjf dlRtid gR RfitgRT afk
) /rr*ioo) }gi?f.
'J>T
ggr gRfSig srg^jkfg RPiRfd gff ^iggiTR Raf^i git afkm gttRg. 3jk
gRTgR ’Jcg = 16
gRR 2
s
■ M OT ^ JiljqflKI 3,,, ^ 3(1,, ^ ^ ̂ ̂
511-73^ 3(ii)] ITO ̂ WTS :
T7IHT PlHf^Rad WT Tf: WTd; 3T8jfe ^f('^) 4?'^'^’'! ^'I'dd 0ldd ̂ ̂# rRUr 1
,) /tj^*ioo) }^,7ft(TJ^) =^,u,{l-('fti1+^i2+
7f[^ = ra pififfir ^ ^ 3iW ^ ^ ̂ arflTcp^ ^
RiPiRfrI ̂ 0lHd I
«
tft i= Pts^ ̂ afPfcT cfSpM ̂ ̂HWn ̂ Pr. ̂ ̂ 3#WT cf5WcT 711^ RRRra ̂ w 4
ftxfRpfPr srjqto RRPiPr ̂ wr €t ̂ ̂ RiRhc^n ^r 3?^^ (^r 4
c^ 'OT (l) "5^ 1 ̂ '^®TT 'd'lPm) ^ccf)4 fc|5f)dl cf^r sipid cfpTO 4)41 cPT wfd^ld I
f^^iratSpT RP[4Pr wr ̂ ̂ ̂ Rif4)^r w4 4 ̂ 3t^ PrPffifM ̂
wn I •
trui 2. cT?q?ErRT PtPtf4fcr aiafe P(c) ̂ atPicf)^ ^Ptrt^ 47#ri ̂[4 ̂ im^41 :
P(c)=P(s)*(l+M/100),^
P(S)= vJ44VcRT WJT 1 4
l\/l= ^e'ct?? oOTqPl ̂ emr #fiT c[)T % 75^ =
^^cbvpTi- TiTfT Pmm#T 31^^ f4f4f4Pr, ^ 5^4 4 3i14cp 4 3t4Pi sn ̂ t ̂ 3t^^
ptf4f4Pr 4 Tj)^-wn4 7f4 3tW ̂ ^4t 44 tjtt PiPIk^ jra4t 4 3?4Pt 3ri 31^ f?iPrf41M 4 ̂
sjTTn4 4t 34to 44i^ 4 44?TcRtt 4t ̂ f?mR ̂ 4 TRwm 444^1 4t ^
Pfiot 3itoT 4Prt, 14fi44 144^ 4 344^1 4Pt?t 4\ 4wn 4 Pf ;
(iii) 44 arjqJ^ PrPrf4Pr 4 3F? 44r4 ̂ ̂pra) f, 3rjfj4 4 7# f sfp PTEfRitPr 3rj{^
^qPif4dm w4 44 14 siP^kF 44^ 444d 4t ̂smpft :
: 44 3T^^ f444f4 3t4cT P(s) 4t ̂ )^ ̂1^4 4t 7i?4 3fPicT 44cT PiMi^'dR 4-iPid 41 v)ii^4 :
FT =
PtPttt 3rjqf4T PrPrt4PT 4 wn4 4r 3fPF 4Pi?r 3fk
16
tRDI 1
P(s)=Pm{l-{Pii+Pi2+...)/N*100)}F4.
Pi4%t PtPTf4Pr 41 44tt, Prar^fPr PiPrPrPr 4 ^JTnTT4 4l 3fpTcT 44?f 4-iPidPn,= 4PTcT
4 fcTTj 41 1 ^
■ PpTHCTqwF4 4l3flw4lFT444TTF4r4PF4l7Tf 73Wcm4lFTPraP:77Tl4«4 44j4f4F^
3T^^ PrPrl4Pr 4 5t^ ̂4, Pi1444 Tra4 4 sft 3t^ 14Pt14Pr (4:1 4 4 (1), 1 4 7i?jt
-tjqPid) 4 jdcf)? oi)im4 4l sfpRT 4PtcT 4 % 41 f41
N= P(xn^ 3T^ 1444P 4 3T^ 7341144^ wl 4 44 31^ 14^^
FW 2. cRTTFira. 31^^ PPrm 3T5jPt P(c) 41 stPrkPT 41ft P-ii^i'diy tfiPrt 41 ftf4 :
P(c)=P(s). {1+M/100),75T?1
P{s)= 73q4FT tRiq 1 4 444h 1477 Trq 31^ 3T^^ f444P 41 ^ 3^
l\/I= ̂ )2^f)^ 41 ̂ 4Ptt FI % 3fp 7J^ = 16
^^4 FT7TT4 41 3ft^ 41ft ̂ 44 T^q 144t^ w4 4 ̂ ̂
SXp 4 44FTF 41 f41 7R Pmr^ f4i 4 TTFTm 444h 41 fMI ^ ̂
Ptt^ 3ftFT 417F PffSPt 3T^ 144f4P 4 3Tf4WT 4^ _
PtFT 417Tf 13fp (3444 41ft. PrqFiT)1
. r
21 FfT % 4 3414^ 1441 FcT 4 44 Itj 41, 73^1 41ft ttrfk ^ ̂
1995 4 34PT STPRjPRT 4l7T^t^73iT4?T(l)^^^^^'
THE GAZETTE OF INDIA : EXTRAORDINARY
[PART 11—Sec. 3(ii)1
• <’> ^ ̂ art!^ arttefM
^ 3jk J1T%I cF5t. ̂ ̂ ̂ 0^ OTm? .W'f^^aff gm f?IW ^̂
3tfi>g>H^^ecJiYcfltTRT=3Tfi^
(2) J ^ 3?t?mKPT gJScfJ? cf^TRl ̂ IRcPR gRT 3mr% gi^cfR 3fl^ ;fajp^'Tf raPlHldT3Tf gm f^iHI^'HK j%TRf gfRjft ; cTPJ 3TrerR'
1^!
arffenr ̂ egR gSt^m = ̂egR g^im + wp[k gR, gfj
te ->7 amrt^ te„7 a, ̂
TTTrt t at w aqte 7rt« gR,« 3rtaJte ™,,Sr ̂
^ ̂ ^ 3fKfM ̂ ̂ gMR 3TTmf^ 3^ ̂
^ gn 3}k 3ng5% gg ̂fnigR 7TT ̂ JIM gR^ ̂ ̂ET ̂
'fraBw ̂ Jira gR^ c^ f?tRft 3Hf
TR^ w 3Tf^ ̂ I
r ̂ ̂ ~^^ ̂
(4) gTRR ̂r ;3gRST ̂ 3TtgfERff c^ ̂ jggR g5^ ̂ ^
Hggg c^ amlgg g?t grf^r c^ ̂ .^.77777 TTrf ^ 3nEn% 3Tig5;5r, ̂ 3ff^ ̂ ̂ ̂
r;- r: --
■31"^, 2012 gg, 3ik 3rfgRTflRf gJt g# f amr ^ ̂TT^ ^ ̂ ̂W^g5^g^^1^°i2^3^ggT^ ? ̂ ̂
3T^^f?lf5rf^gngng?frgggg75[5TRgR;Hc^^HH7^ ^ ^ ̂ 3T^ 1^
Smi5, Si ?^31*'5’2^’ **** ^ ^ ®'^f^f^) 3TT^, 1995, 3,£j^ ^,7^ ^ 3^. ^ 3rf?Rj[^ gft f aftgl?! (gatgcf
ate»® « ate at* ftro OT lilftit teirtt »=» ate ftftefa
^ ̂ » fitefflteS an atfl*, atetef * *, If; ̂ * T* (^
atftajjte « #. airt aai art aigfe 30 wt anaa ^ '■’^^
^^70 ̂ ^a* te ^
WateititaSaifin^aaiaaafiiaaaiaaaa^teteaTOrttinrXf ^ '^'
« " r*" ”11. artteEin aSaa ai Dai aS mjaa aflaa _(,i teiate,.,*,*, ^
at, ata a* gaaa (ate ta^ ^ ̂ ̂ ^
(g5tgg f^rggR) 3n^,
ggi
. - [WI-II-131IS 3(ii)] 7lira ̂ TTTO : smiwi
^ M 3jk ^ ^ffrRf ̂ ciffriH, ̂ -qanl^, ■ WgIT IIT W^ ̂ ̂ ̂ ̂ ̂
WTT^ I
(2) 31^^ if ̂ RiPiffil^ ̂ 7|w ̂ cfn ̂ Tf, 3fmf^ 3!k ;RTm ̂fTFnfr
3rf?li%JnT, 1940 (1940 ̂ 23) Sik 3T^ sRT^J ̂ kflRt "JI^TT RPlR'^C 3fp^f& c^ ̂ TTcpf PlHcl^
3ncf)R ^ 3)j'(^Rid RiPiRfci ̂ uajif^iflr, arf^rcpcw cf^kRT ̂ ^ ttwit ̂
c^ ̂ ̂r villi'•'FT sfk-'ki 5 ̂ ̂ ̂dctivi gfTRcT ;FRr Wr ̂ fk<? sri^ % afr^f^ ̂
;rtcr ^ wn ̂ wr ̂ ̂ ̂ I
12. (^Pl4dl 5RT 3fR3T ti^ 31|cl!<^ch WkfM cJi) ^ ̂i Rf^Wfcl^if ^n v^ARcj, 'ttni^x)
c^) c^^ira- (i) 3rjqf%H [^PiP)Rf ̂ arm ̂ f^Pinldi wfiR ̂ ̂ ^ Rdd
cfi) 7|^ aif&wfT ̂ fikcT ̂ 3r5?jf^ RPiRId cf5t cfikH Piw feP? ̂ <Rra ?kT I
(2) 1?tRff SRT rapinldl ̂ fcRPIPT site ̂ 3frW WT t cj?T ̂ 13 ̂ ̂ET c^F], I
f?kniH QPlHi^aft c^ fktj 3i^<jRra f^Pi(Jfrd<ii eit) ci5kRT- (i) ^^reiiR ̂ f?T wr kRRf q^t 3jk
aifiRjfeT ̂ srflrcfKFT cfikcT (eft W^IeT gR, kt elF; ^ 3#^ c[5kcT eR 3rjqJ^ ftMM iftts EJT
FTEtkEf) EIT ̂ vhMld'it cFT ^ 3lj'tirtld RPiRfM E^ RlR^rfdl, 3rf^|EFdF ̂ itFcf (EFT TfarFftEI cfR Tiff FTFJ
#) 3FTf?lEF Rift -kft RPlffiRiq't cfft cfftFR ̂ STEftgrft Efkft :
ERg fftftftr 3T^T3l^ En srftor ̂ ̂ 3t%eftt cfft c^Fftn eft ijft ef^R ft ret^ 3?^#^
f^RWRiftr eft FFTk ft, fftfftEftdT ftrft 3Tf?RJ^ ^ dlftEJ eft ftdTFftR fftF gft 3fEt^ ̂ ftftR ETg- RiftkftcT efikn ffti
ftEftF 3T^T3j^ fftfftfftfft ̂ wtoF ̂TSefR ftftTFI 3rf?fWT-^ftERr (EFT WfttET EfR, Fft RFJ, ̂ ) Eft 3Tf?mT F # I
(2) ̂ EIT fttftjfteF RT 3T^Tjf^ rafftIftfftEft ^ fttftf EfRTERf Efft fttf Ejft ST^qt^ 1ft1ftfftf!rEft ^ Efflft fftOTFT
fftkpftdT, EfTRfiR lRT‘|R TfefTRlftEm 3k3Tf6RjklR 3Tl?Te^ (EFT EfSJTEftEI efR Rt RF; #) Eft efftlFT TR
feRJFFT STEFft 3^?!?^^ ̂ RefR cfftTfR wft Rftft 1 ' ■ ̂_
(3) ftR 16 ̂ REjftR (2) 3ik EJEfftR (3) ̂ EJEfftftf eft STJRR, ijft Efft ̂ W ̂ EfftifR EfJREfi ft ^
3T^RR 3rfftRdF ̂ RefR cftkFT ft grfftcF Wraft ̂ RT EfTRcft t :
ER^ sfteF cfftFcT ^TJ^TEfT ft fftR^ ̂ ̂ ft, ftR 16 ̂ REf ftR (4) eft ESEtM eft ar^RR eftidd ft 'RRRFft
13.
epft efft RFFft I
14. 3rj#R fftfftfftfitElf Eftt arfIjEBRR Eftkra EJH fftEIRR ^ (1) EfFaTR, EIRTf^, % 4 3ik ftR 6 ̂ EJElftftT Eft
:, 3FR}feT RllftfftRTEft ̂ STfeFTR ̂ fftEFT afk 371^^ Rftftt 3fk efftf fftfftEftdT R^ IRT ̂
iftRR ̂ R^ 3fk 3TlftR}i^ 3TfSRFTR ̂ (RR EfSRftjR gR Rt RFJ, ̂ ) Eft R^IcR EfftRR eR 31^1^
(ft Pi 1ft fcl ft) Rft R^ ftftRT I -
(2) RTBT Efftt EfRRTR ̂ IftlftR^RT (ftEFT ̂ et^ sik 3fpR3l^.3ltftranTR EfftRR (eR EfRFftEI R? Efft ft t RFJ ̂ ) Eft
3fPfR E3Rra7 RftRR er (ftlftlftPr Rft ftRR t EffT ftRT fftPlRtR-3TfSlR^ 3FTT^
ftEft arfftEp MR Rft RT^ ̂ E3Fn gRft cfiT RTEfl ̂ I
lisT^^ f^f^^f5^fM Eft IftaRTR fftfftRhnaft Eft fftiET 3ftEifii
(1) RWR "EtiWleftl^eftlftlPleRT" Eft (^■^(dl ER 3ftRf?lEff R?t ycep\ cfilddl Rft (^miR^.I RRft ^
anftR ^ SlPFqRRT ^ RTR IftR ^ ftiRR ^ ̂ ̂ ^ ̂ ̂ ̂ .
(7^ RSt STTERElefi afraPlEft Rft R^ ̂ ft ERTTfftPrt^ 3» RR Efft^ f^TH fftPFftcTT E|RRT 3fk R^T
REft3»RR3nRTEfRdTt, Ef^ft^ f?l™ ^^^^TT^R Rft 3T^ 2 ^ 3fEftR fftPlf^ TFOT 1 ft
Eft ft# R^ 3ftEft?r Rft EfftTRI Eft Ejft R^ftRR ft ? (kEf SnftRR RkRT 1
(3) ret ftR (2) # 3I#R 3TTftRR Rft Jnf^ er ^TviTR tf REIRSI Rf sftRflf # ̂ ̂ ^
ftR (1) ^ REk# ^ 3f^ IftEFT Rkftt 3jk RTRR ft ST^etR^ rI 3fmf^ R5t RRT ft.R^
Eift 3TftfftR Rkftt # "EfJTRk^TFftfftEfR" ftT kt^ er anft^ # RTW rM stk
3T^RR,
TlRjR
RitRR ftR 5 # RET
Rft fftftiR# Rft e{8TT# EfTfftIftr , . ^ . .. „ ,anftRR Efft TTTf^ # #R fftR ^ ftkR RWR Rft Rf 3ftE^ # ̂ RR5R EftkR eftt TReTRRR RkRT 1
8 THE GAZETTE OF INDIA : EXTRAORDINARY. [PART II—SEC. 3(ii)]
(4) ^ ̂ (3) 3T#T ^ Rlf^ tIY ^ 3ihf& ̂ #?T #fK'
3ik M M ̂ 3H^ ̂ H 3n^ cf^r HPj ̂ I
(5) ̂ 3rjg|^ ^ teiH 1 ^r ̂ sihf^ cf5t cfftrT^i ar^H'icjH ̂ an^l^ Wr
^r 3WW WT t ̂ ̂ fcrfM^r tiWK INI 3ik aif^Rjf^ ̂ ci?Ntt ̂ arf^ra? ^ ̂rrf^
3l1%f^ SIM yRT ̂ ̂ ̂ ̂ I
(6) 3rjq[lRT [^iPiRlci ̂ %nTH f^rPiHldi ^mcim irt ^ ci?[tri (ept Rsnik cr ̂ ̂
^ ̂I^RR ci5[tm M M ̂ 3iW^ cffr ̂ sk ̂ f?rfMdT ̂ ̂ ^r ̂ ̂JIWN IRT ^ ̂ ̂isg?7
cfW (eft w=ftTi cM ̂ ̂ ̂) ̂ i3raicR t|?[Trci M af!^ gir ̂ trit ttmt ̂ sirtt t ttI ̂ aft^ csj ̂
RPinldi aite Tmrftd w^r ̂ ^ arflrf^ aif?M Ji^uRd ^^ di^ ̂ ̂ cp^ dd dFft ̂ I
16. 3I^^j[%d C^ arfijcPdTI clJtnd cBT gd<[«ni -- (l) ^ 1 arfe gfr m TJ^,
gif ̂ cnf^ aflcp cffiw (;g^ an^ c^ arjuN aij^Rid RPiffifci^l arUtcpcR ciJtdd
dit cfiMl aik,d^ cf5t i aii^di aif^t^|tid giMl I
(2) ^,anEMMd^^aii[dfdM^rTT^ ¥R3T^T3l^idf?rf%WM cf5t
sifeRPT fddJY dfldd (TPT 3IR it) d^r afk ?Ri ̂ 4 RNdM cpT ditt Tji argjfldd 3lif$Id d^ #dT i
(3) ^ di^^r dddEPiit d5t diEft t Tfr gditOT ̂ id? dtt aicrf^i c^ itcNddw - 2'^r di dt
^<?lq^|p|0 dl dNdftdJ ̂ if RNdJR d^T aiTifid %dT dlppiT aiW dd id c^ ai^d Wdddit d 1^ did! dd
sitedd gidcM didd (dd aiN it) ̂ 5dftdM d fiid uni ^ did ^r aiat Bdidi afk dd^ f^Rdldi ̂
gdifer -^ticPdd ̂ iddJR didd (dd aiR it) ̂ ailid) dlf^ Wd di aiUM diid ̂ di diin ̂
dtid ufdl dTdi ̂ diit ̂ I
W ̂ ^^t d?n i, aifidRid jddJR dttdd i .ddfeiiit dntt M afk fifid ai^^
dT' dMiY i ddcTST fikrtM ̂ didi i gdifei atfididd didd di aifid^ dft drirf i iji fiftdtdi
M aifgRjddT di diife c^ 45 fid ci 3idfi c^ itdd d? ̂fiRdd dki f?d i# ai^^jkid fifififi di aiflicpdd
^ddid df^ (dd aiR it) gdif^d aifidHid dftdd (dd witd ̂ kr did]; #) ̂ ai1?M d ̂ afk ̂ 5Td dii
i dndddit ddddd di ii c^ 15 fid dft aidfi ̂ itdd ddd - 2 i di if -^ct-KiPich di dRdfidj wi i
ikt uHdit I ,
dd M SJM
#
• (5) d^ (4) c^ aiEftd ^ijddT di d fid dTfi di aiflmidd ̂ ddF didd (ddaiNit) i an^itchFi w i Miid
, ^ ak dd^ fifidfdi sid? didd ̂ gddid^ i fiw M aridikd gdif^id aificpdd ^fidd i 3#cp
ddikd dPd ̂ did i kr 3ifiM sdR ki di dkki k stm kdiduidT^kfcid^ d̂T 1
dt^’ql^d fifiRRf ̂ dJT dditR-17.
(1) TdTdd afk ̂ RdK EPedM ddldld k dTJddl dPd ̂ k did fid k iftdd dWId 'gRI ddd ai^^j^i) k ddidd '
k kd ^Idd f, di^ dRi Id fifiddd fkdi diddi afk ddd ai^^ i dkidd (ddiddf) di ddkaFi, dfi
31^ t, akRjf^ fidiT Fiddi afk ddk dddid aifkjddi k ndddid di dika k did fid di aidfi k itdd ?d
anidi k dddk k argdR nsjd arfqkt k d^ d^ affdfM k fkd aifidnid ktdd fkdd fkdi
(2) damai^kdiddidf afNkkkai^i!j^fififkfMkMk.kkEftd#k 1
TfidH difkdi andk (dddkt) k antM M aifkdidd ktdd dd gdkeM dfidid difidj aiTdk k ddd k .aHEIId dd aif&didd ktdd dn gdk^FI cbwfrid fkdT ddddl—
(i) kk ̂ aik did ̂ «d -aik dkdR dRdM ddidw m dndddd^ afkfik kt ^ gdkfei kit t di ?d
anidi k aisid aifiddid didd krad dRi di dkkd k dtd di ki dR, kt it d?k k ;
^ ̂ ^ fifidfdiaff kt kw, di ;MdM gRi fidd aid aifidfkd aifididd ̂ k
ddgxR dfidid k dddd dT> ddk aifid? ktdd fiPiRfik k fkd ̂ f, fii?T kt diikf di dm fiwi ddkt
k^ k fifidtdrai gRi d^ dfkdd di ddk aifim kt ddft kt df k ; .
dmpTi I
18.
(if)
9qR(i ̂ WR : sraiwn[WT 3(ii)]
cfft wsm, ̂ ^ pRicT arf^fcfi^ ^ ̂r^kr Rlci^id(iii) ^ M ^
^ cfiH ̂ ^ ̂ 3Tq^ 31^^ RRRIM ̂ fki? ̂ f. R^ ̂ ̂ ̂ Rmn ̂
^ RRdWoft ̂ M-ccfl't^ MR?ld TIT vJ'H'A srf^ ̂ <|(^ ̂ ̂ t I
^(^C|5^- TT^ (ii) 3jk TK (iii) ̂ ̂rakFf ̂ R^ ̂ cfkki, arRw^ c^ ̂ ?Tkki M.
2012 ̂ 3fk ̂ ̂ dwid^ ̂ aM ̂ Rr arR^fKRT cfJtro R- g^aM ̂ ̂ l
cjjRttpj R 3f55R 3jRR R stRciKm ̂ m Ra^m- w 3tR?t ^ sRR^ R^tft to R ̂
tt^R) tR sfRRR^
19.
^ ift SRTOm ̂ RRkRR Rt ̂ RIRTO, ̂ el'icrjRd ^ SflcRTO R1
3itoTO RR^ ̂ ^ ̂ smR R Rt^. Rki ̂ ^ ̂ ̂ 5
R ̂ 3iRR ̂ siRronT RRci ̂ RR^ Rto Rt t 3(k arf^Rjf^ t ̂ ,
^ ETO ̂ ̂ mr aiRronr ̂ ̂ RR^ ̂f ̂ ̂ EfRt cp^ R Rf?. ̂ R tot ■^,
srpn-^^eRRl
iR 31'i^iRra RRRRR ^ Rl+id Rt ^rrife^ titot—
fi)\RTO^R RRR Rt^ toRt RRRRR R f ̂ stRtoh ^ RRtt ^
Ur RkTO#rl^ ^ ^ ̂ 3TRTO3T RR^3iRtoh|TO. Rtro. R ^R!RRfR3lfeTRt^l^TOF^RRTO^R^3fkTOT^^^.^^^^^^^
^ WTOT R Rt^ 3TRTOrfT ^t5to TfRra R ^ tiRto R tot ot to Rrrn tottt I
(2) W)*n wfSi * 3«^. OTite ^ « If*^ ̂
R'Rtt?^ I
21 3rj#TT RRRRR Rt ^
,.) ^ fliMtW * amftg aWM it ataflfe ^_jR^* ” fWifW * filftftfirat <i arafc ^ifiiw »rtl t RPiHfdi
20.
Rt ttiRto ejRR Rk arjqfRd
^snRfi R WT-ill ^r^8nRar#Ta R^rf ^qroiRn 1 ^
M flRS 3mSra ftmsi m f»Wai, ^ ftp* wi ^ ^
™ 1^-11 * aw- iv it'?Vra sflaawW W9,a art ft ftft arate ate« frt ft ftwl^ « ftE rt ft aftte aft6 ft ftft ftfftte rt a=Hfto ftft* ®
R 3TtfR R^ Rtai R) ^ aik ^ aiRR RRti ^’Tcjtot ^3iRR Rkra RRroi 3tt^, i97922.
TOT TJTOT-
aitei ft aftfc ftrttera ft lftiaftrt^ft" ftMa. araraa a ftawft aaifftjftafta ft aate nw (,^,3 p^aa) afta, 1979 ft atestep w rt
i[2R^tR, tot toh Rt tot ^
(1) TOTO, ^
sRsn TO toRTt Rt ^ sn^ R tttR tk ^
3M?T RRcT toto igR to TfTkn afk RRRttt, 3TTtttto tit ^tetaftftftftteftiawwaftfteftftftfrt:«rtrt, aartal ^
TT^ 3RR RRtt TOcfTOT Rtot TOT, RR RT^ R, afk TOkr (1)(2) an^ R ttttoTO ^n
tot 1^ TOT Rf^r R Rr toRt RR- cfRra R Ret RT TOft Tn TrsirkkR
■OTTOTTTT 3k T3TOT TfnfRcfJf?mTO, Tienf^, eR ttRettto tjto 3fk totoi^
Rt tR Rtro ttt 3tRR Rt RRt RTto er
(cp) RRhRt, 3TTTI1TO TJT
totto ^r ^ R ttR^ R Rtv ^
Rttto TgRkTO Epk tl ■gETTO Epk R Rrq ;5ateftaftrti«ftft«aftwraOTftrtia,artftftr!3rt;rt7
Aa^ftteft afft^aftftftrtateftaiyfttewteft ft tei I(Eg) toto tot
(TT) •krg Rto afk RRtReR ^r tot RtR
/9^g (503'22-
10 . THE GAZETTE OF INDIA ; EXTRAORDINARY [Part II—Sec. 3(ii)]
3M?r gW 1979 alk 1995 aisfi^ a^iRiRltra c^t g^—
3TT^ ̂ 3TTTf^ gRi ^ ̂ amn^chl w f^RRcffr % TTsjrfMl
TO? gT?I (g5^ m^) 3TT^, 1987 sfk 3« f^lTO) 311^, 1995 ̂ ̂ ̂
^ ̂ 3rf^ m\f^ g5kn c^ crm jti^ wr gst ??t 3tt^ c^ srtfH gpn g^ srA^g
g^M I
23.
aRT f^rgg gfNg git ggrg eini, vixicoi ^rgggfg gft? vj^cbi
om ̂ ^ f^, f?TO 3TfligKTg gitgg (gm ̂ g?^ Tif|g), grigro ijr
™ (ggciTR^) ̂ arf^igr t. tot ftMgr arf^rgRig grggr? gitgg (ggaiM) c^ 3if?TgRPT gitgg (gm
TgT%T gr^ ?Tf|g) ̂ sfl^rgr g ̂ ^arg grVn :
WfTf^gT'TO^TOTJ^mgkrafgRjggr c^ mto git cTr5te ^ Wn f^T ̂ ̂ g?- ;gi^rf?^ grW
^■^Igd RPintrd git ^rgg^r gitgg arflrgRTg ^rggrg gitgg (ggr rt^ ?gi%j cp^ 3#gj ^ ^ i
(2) TR^ 3T^ mm ̂ mg.^ 3TT?Tf?RT mm mg w fm ^ mm ̂ aggn ^ ^
^ ̂ ̂ ^ ^ ̂ ?ng m?m
gr ^ m gg g?T mm git mgrgg gm g^ 3TTgrf% sTtmig TTO? m gm mg
^^^jggg m git mf^RT gm I(3^J^ f^, TO a«, 3^1, ^ ̂ ̂ ̂ j, ^ ̂ ^ ̂ ̂ ̂
(4) jRm ^jggrg mm afk m^gj tmgtrn gRr m m? gg ^ ^ gm?
??T t % gm ggggt gg mt cgm c^ f^
- ■ ^ ̂ git mm gm i25. ^ arj^f^RT mrfmgt git gitgg m vjmt g>Ng ^ gg gtggm—
(1) jRm ^ 3T^^ mm mg ^ m anm mm m
g? ?Rgg? grg to ir 'gg^ srmrnr
m?T m gg ^ tmmr gft srfmmr'
Tfggfm gm I
24. TRgg?
ggj?
mg;
g?
ggggi? git ??t. ggg? ^ mr m
gfg TOT ■^, ggt mm mtt mggrg^g mg g? gitgg ?j^t
Big fgei ^r mm mmg ^ m?
5?^^’mgrgif ' mt mg' mt ^ mg mm gr
gitgg m gm ^rmp? mg m ^ m gjggg m git
^ ftroif m-TO? grg to-to g? toI^ gimt ^ m gwr vif
^ grgtggrogit^gggg
RPtRRg'l tmg gitgg gg fi|g?iui
mm. gg mg mtt mrmg git gitgg if mm gitgg
^’tt mg^, T^3Tfmgitggg?g^gTt;
^ ^ mmgf gg f^grm grm ^ mg—
m t^TO mtt mm git ^ gigr-^ Tjgr gitgrr g? ^ mm git ggr
g^ gm I
26.
gr gm m gr aggrg ^
27.
3T^gRT gitgg rfr mrgr mrg
mmi, amFPft gr mjgr aftm gg mg ^ ^ g# cp^_
3Tm m ggrgg grgrft grmtgg,
N gitf mggr m gig ggro mtt am g^ ^ am ^
tgmg gr mg m ?gg? g^ gm i
28.
1940 (i94ogg23) ^Bgggfafkg
5f^ ^
marmggTgggfm^aTmm
m 3TTmRT ggmr git mg git
[TO 3(ii)] TOT ̂ TITO3 : 3reHlR’'I. 11
29. 3rfil^ cjit WIT 3ik Mam fc^xj ̂ ci^rt—
W'^1’ aTcRTcff <^f5dJict feni xn sm dr arraif^ 3ik ^ Mxr
afNf^ cfiT uff ift HiHdi cPT arMxs' ■??tdT 3ik sik ^-aik tiwt? sm rr-rr
XR d?TT k'5Rld ^ SIR 3iM?I ifr Rkn 3fR ^aWR ck f!tRft 3TMr X[ft RPT 3fk f^PlHldl k dtkR W
arfiTk® Mam Mr xf5^ ?Tf^ M 1
30. tM, delT# 3jk StMir ?Tf^—
(i) ^TRdjR dT R3?T RjcfR? cpT kk M dwrM arMrk, Mr ^ f%M xjsnf^jfcr, dr wr
. "awR ^ 1M Rsirm ^ Mr snM srar sif^r^ Mn -w ^ arjaiRd 'ijhf^'dd M m 3tw
XlF RnXTH M dft ^ k kl ^ 3TT^T Msff XR ST^qraFT Mn w t—
(r) fM wr m jM gR Mn afk dMt k Mn ;
(fi) fM M kr, Rw M Tj? t f% ^ 3M tM Met rt Mejr Mr.^n t, fM
RT t ttt Mrr M cnea t, xaM ^ arrEipfr, M ar anMr rM Mkr w siMr Mt maft t, ar srfkj^
dR Mn, 3fR ddl^dld. RIliricHEJ iTxrRMME^MMkrf^f^RT^^ Rdc|5t R;RTT M M
aTraRR dara Mr I ■ ' . ■ -
(a) fM aMm, M M-M ar dETR-M, M-afM srk afMiat saa-Ma Mt stMei kr MM
aiaa M aM t f% fM aM e^ Ma er Maa Mn aar t, Mtt rt a?T t ar Ma rt^ etirt t, arkpj^
eirreM I
-1(6^
(2) aMt 3fR 3tM?r k aaM ts aMa rMt, 1973 (1974 aa 2) Ef^ aim 100 e^ Ma aar aaa, ^
3oM E^ 3M dRraft 3ik srMmr EfTt RTEj I
^afEfR)c}R a?t 3tM E^'kr4, kasafkkaeE^ REfta rt^ Ejfr a^ Mft Rf^r^qaar ar aM
^ eziM Eak caM M Rf^r^par ar aM ^ gaMfrERi ^ M rwr ept aarM!r, REiara ^r M Rt^r^Jk^ e^
a^TRa Ek Mtj ^ ar rM gra M aa^ arar eM e^ Mn k a^ M e^ '4M rtM ert Mar M
awR Mr Ei^ rM aa^, rtM aa rt^ ert Mfr :
- a^ Ra^ ^ E^ REfia aaga M aa Ri^ m ^ Mr?aa M Rt^ aarM!r, fMt at sfMr
ar R^'Tj'i^d RPiRfri er Ma awR gra M afraa k rIeTep ejMt aa, Rt arMaa Ejrtaa ar e^Mr
aMr k asTrM!r, rMt it M# ̂ «m Et M RT^ Rett t i
cpMa araat ^ la rM e6 RaaEtr ert rtej^ atf #tt—
la 3tM ^ Raaa Mrfkfea ept cTpj att #Et, _
(i) aiafra ^tfe arMraa, 1970 (1970 er 39) (Rina tfe) ^ e^ at Mt at siMr M arjaEna a
Mra E^ aiEaa a MM Ek ana, Rt ^ sfk RdiiRd a it, Raan Rirraa eM ark fM Mratar at af^ a^
ta t laEt aiRif^ai Rcaiaa Et araa at aM k ata a^ at Raft et? M
(ii) arata tta arftMa, 1970 (1970 an 39) (aMrr ^ REfta tfe at at Mt at sfMr an t?t
srgaETTa Rk ftaaa e^ arsaa tr MM at at Mt atta aMn aiR ta t Rarraa aRt ark Mratar at ta t
arkrMEP Rinaa ^ arta at artTi tr ata a^ ,at Raft ^ M
(iii) arar t iM ararR arjaTaa at artTi tr aia a^ at sraft ^ M aTjaaia sfk Mrt Et arraa k
ftaM fM at akara aMt at 3icrtM aRt arkt Mt at Mft ER RRTaa aRt ark Mratn at:
atg IR tar Et Raaa att tit Ra Rkft airftaaar (araa) k M R^ ^ffaft an arjataa aatt area att
a-kfitR at RWR Et araR a^ga ftan aar 11
RT^taRDT—IR Ritm k rrM MtarakittiaktiRtREt aM Et M‘at Rkkr' an att r4 trar Rt
sftaft Rk aRiaa anart Ma, 1945 at Ma i22R^ Et aiEfta Rk Mr aar t l
31.
32.
[an.k. 31011/17/2012-tthll]
k'g ERktktaR, kgaa afta
12 THE GAZETTE OF INDIA : EXTRAORDINARY [Part II—Sec. 3(ii)l
(y
RT.-msrftcfj, ft- f|#!T,
^ 2011 i
flM : 1 -UoJiiJftifl/
1.1 BPJiosr sfk
M?9I5?if gar ̂ ̂ ^ mmm
fe, ?■mi
iedisi jiftcT fs., ?. ?3M?rBr
3U$nhciil<n fe, ?■
10 fezr. / fWk,
50 ^
(hci'nipm w., fe, ? JstteiW
gfl?gg 3UitUl$B W., fe, ?
SZVcftflolol ^■, fe, ? ?oM?for
fe, ? ?cufcf?rgf 0.5 azi., 1 gz. TOS7
tzzto eS 3z# ggigezz
?sMm
Sffui(Z?ZoZ
?
^■, fe, ? 1% 3zraH
1.2 czteer GgfldfeiW
?3r^izz'
.11^^
0.25%, 0.5%, 0.5%
te?Z? flftfZ
7.5% H^^fZ^r
fe, ? BSx^lcJ
sfffpm
goof^fcZG
i-Hlutnal
2.5%,inonhm BT?^lmk[?s 97., fe, ? 1.2%,
5%+7.5%
1%, 2%+ tZgioiieiigoj
■ I.-200,000
(etomivm bi^$}cMhi^g
+ CS}otle(l$at 97., fe, ? poufeZoZ
«7te ^ az^ ?gz5EZ7
^CTGgfZ? izfa
1.3 At'zI'JJ/ccJ 3ff^c^Er/o(
igz^?
pgfqisoz 5?!^ “
gg7.) 3zk M^z cpTo? fzz^ e?jf smmfh)
M gg7 ^ ̂ q^ .qf^asr
97., fe, ? fouJcrtZoT , 0.6 f^. /f^
5 fesz.
5 ftrazz.
2 ftw./5
5 Pm.
^Ppri
pou[cz?Z5?Z7
ftzOTP
mtfksi
97., f^., ^fezzufZTzsr
fe, ?
PiBl^lc^ 1 ft^ZZ. /
5
9Z., fe, ? gou)[/fZoZ
3{hm?at Hcqfe fe, ? goufcRZoZ 10 ftwz. / ftftz^Pmm?af 9Z., fe, ^ few 5 few. / 5 fefe
■"■' " oSS.Sf*”' ’TO * few <» !I5W 55I5,rt
2.1: 3iliqq,9.8 ipravafeEg I'ldMizz'd^ch 3<hr Wt^Vtficz t?IVbM
597 w crOm/M^ qW
9Eniw
5iizifel'
.liiHcir
cTaiT
fwi Il-T3^3(ii)] 'ira ̂ ; 3raiVRni . 13
■Mkfkfciiis# m., fS; if 325 Pm.,3S0 fimi. 'ms
sitfmt 50• ?
25 fmi. /
•)i\[ciiii 200 fmi., 400 fmi.
100 fkwj MkVI., fe, ?
ftfW
^■, fe, ? 150 ^m. /
yr., fe., $ 125 f^OT. / 5
^ilfkci'itlel
VI; fe'. ? 3i?#erar 500 ter.
gl'y fe. ? esr?5«r2rrf>srte, srrfisr. 80 tejf., 170 ter.
2.2 silftijig-s XJ^ulRicr)
.■raw
10 tejr. / /i)rf^
tewfoT Heite fe, ?
10 fter.arbiter
gostersf 50 ter./ ter
50 ter.,100 tef.fe, ?pirm
50 / ter 2. iteBrraer
fe, ? g3u/cr?rsr
2.3 ■'TFaC ^dlvjl qciigd
100 ter.fe, ? a/ter'
0.5 .ter.at/teriptesftfte fe , ?
2.4 R^j'A'eigs 4 Tigaa ^ ai^ ^
50 ter.a/ter'mfmtm ' fe., ?
5 ter., 7.5 ter., 10 ter.arfterfe. ?
500 ter.atter ■fe., ?
?nte Tit
fey ? aritef ■ 200 ter.
10 ter., 20 ter.
6rggk<!fl4et?flcrtffaf
aSte/fe, ?
V
srjcRTwrr:
?gr ^ w ^M -TOaar
I 'ter. / terssi^mVl; f^; ^usUicim
4 ter.arJftergr., fe., ?ttcilMIkil-Hl^di ^Ms
0.5 fkwi. / 5 terter^■, fey gmtis
0.5 fter.ar/terrgr., fey ?
4 ter. /pouJcTfror
100 ter.goxtorsrgr., fe, ?a?tear ggirMg . ri.
22.75 ter. / ter
s ter., 10 ter., 20
ter.
gsr^rargfy fey gt^terarrgar
aitterfgr., fe, ?^sterMsr-'e
10 ter., 25 ter.aiWteTgfy fe, ?stf^aiuirgar
5 ter. / 5 terfter
fllPToT <I)t rn^
10 ter.
5 ter./ ter
aittergr., f^., ?
ter
14 THE GAZETTE OF INDIA : EXTRAORDINARY [Part II—Sec. 3(ii)]
Tjfeste ajh 3FZIwi; 4 -
#
, Jimm
gf-, fS; ? 3itm
A
jwaar
gf-, fe, ?
gl., fe, ?
?o^qf?fSr 1 ft̂ ./
Kfjfofe ̂ oW fS^jof l<[fntJc)oc;
fSw
<^[c^M3{ dcj^cplaic
iii'^[i'UUni'Hl$‘!l iitni^c^d
gr., fe, ? 100 fegr./
500 Pm.
10 ftw./
fe-, ? pouJerefoT
fksmcdk^it^ppi. -<teiUi$^ fe, ? . ^quJcf?fof
■ fe, ? 250
fe, g gsufegfgf sarar. sraifsji7gf so ftw./ ̂
pj ̂ m./ Mk
■ 30 ^
250 ft®./ ftft
0.4 ft®./ ftft
25 ft®./ ftft
gor^fof1
alftgaf ®?^ fe, g goi^for
fe. ? ?ou[cr?f^
ojcnicfrtft g;., fe, g gcujggfBT
goulg?^'mhi?? gr-, fe, ?
f 2-ift?CT j
viil^d g?t Ti^ ggi^ :
VSl-i^dlcieiemtHi-rcet gr., fe, ? 200 fkmj ikfk
[5 ftft j
’^rn : 5 - lif^toi'iqcitic/l'IS^Rf^fScm
ggr/gi M ■
gr., fe, ?
g® ̂ ̂ dilm/'it^ mk
Mmm®tftftP7I?ar
3flft®
„ ft®
-100 ft®.
200 ft®.
100 IPf®./S ftft
ft®®!?® ■ gr., ft., ? ?akcf?m S ft?®. / ft?ft
^ktmfkdct -
ft., ? ■ ?akcf^m 500 ftaj?. / I^fft
30 ft?®., 60 ft?®.
200 ft?®./ ftft
20 ft?®./5 ft?ft
50 ft?®.,
100 ft?®.
25 ft?®./ ftft
50 ft?®./ ftft
200 ft?®.,
500 ft?®.
200 ft?®./5 ftft
100. ft?®./ ftfftr
gf., fe, ?
fe, ?
gf., fe., g
a?[ft?®'
5ot^?o?
ft?®
ktfkm gf., fe, ? 3?ft a?ft7!?/
ft??T?-
pni^c???ff?
?7?fega? gg., %., ? a^ft?®
ft?®
? ?akc{?[a{
!?iil4d c?lt ggiggt
(??ft?oft??a?
? 2 ft®./ ftft
6.1
??m ; 6 -
[vpill--ign5 3(ii)] 15^ TTTO : 3raT»^R0I
#
6.1.1
<<u^ni M 531 ̂ Wl ’^4 Mmm
m., ? . ■„ 4tfcM{ ' 400 Pm.
200 Pm./ 5 Pifk
Gei^Bgii^tcf
4
%llPld tfit
■ W., fS., ? dilPini 4.5 m.
750 ft®./5 ftfkTrJe^sfor
6.1.2 TjfePRclRilcf
337 ^331^31' . .>130137
. 50 Pm.V; fe, ? 3!tfe3fgr^ajt^ei^-ltrfqnggf
6.1.3 TjfefWiW 3ik Tjf^f^^ldl-s
337 ^ ®T W&m/4tit^^ .33r^7 .173337
37?fe37 . 600 -ftrOT.fe, ?^faf3^oE3
6.2
6:2.1 ^3Tel3CT 33T537
337 ^ Srfter/Si^i?’331^37 ."13S37
125 to?. A 5 tor
250 Pm., 500 Pm.
250 to3., 500 Pm.
125 tor. / 5 tor
500 tor.
>H3£r7 3fk m4o'f[<>ife, ?itorflfeto
fi^^rgcT
>33S7 3f!7 Tn-tof^w., fe, 5
jJffufefoT
6 07773,12 51773
125 Pm., 250 to.
500 ton.
53T3?3?r^^3uns7r?s7 ^ou«w liPifRlkoi 71., fe., ?
fCT^3?Jof
250 tor.,1 3zr.fe.,' $
fe, ?
i^tpsrftto
250 to., 1 m.?oo?cf?rsrd<t>/$3l377k
125 tor. / 5 to(
250 Pm., 500 Pm.
PmVI., ft; ^MctPtm
<kr^
250 Pm.. 500 tor.
250 Pm.
125 to ./ 5 f^rfe
VI., ft; t F™/c7?[ar^Unnflfk<n
Mkrs ■
3nfto 33I53t
625 Pm.
228.5 tor./5 tor
600 Pm., 1.2 4tr.
arttof
>77337 3rt7
?o5fe?rcr
mkdfp{fcm+w^s^jvtPpp iPfs ?
100, 200 to.■ alitor^P?(km ?
6.2.2 3Rl
.>73073733l^3f
250 Pm. / 2 torgm^irfrarfe., ?i ’' otopitor
100, 250,500 Pm.
100 toi7./5 PrPr
■ 500 Pm.
aritor'
37>}o,,
fox/lclVl^
?ai3^cf^'[or
• adtorr ■
pfiirsrtoto fe, ?
iX ton./100 to^
, 250 Pm., 500 toar.nr., fe., gPiUheikilPl 6l$iUciUl$^
80 + 400 Pm.,arfiornT
Titoorar
sr., ft., ?
• 160 + 800 Pm.
40 + 200 Pm. /. 5 ton
[ uc’prPrmuw'^lei} '
^ ,,
100 Pm.aiitofgr., ft; ?sr357to5^to
125 to./ 5 tor
250 fto., 500 Pm.
10 fto./tor, 40
Pm. /fkfei
200 toir.,400 to.
500 tor./100 tor
to
"adtor?7.,:'ft., ?Gftaftrjftrar utcMc
ptiu!cf?rorg7.,-.ft., ^torarrgto
aritor
?ouicf?ror
37., ift., ?,A^fksi4lel
. 16 THE GAZETTE OF INDIA : EXTRAORDINARY [Part II—Sec. 3(ii)]
ftiw loo ikfk
fey ? 100
ft; ? ’iUfkni 500 ̂ m.
500ft^.,1 W.?
6.2.3
591^ M .>13331
gr., fe, ? 50 Pm.,m ̂ m.mijpl
tmtoi ft; ? aiWeraf 50 tor., 100 fezr.
13., ft; ? 3it7 3Z?fe?3r
6.2.4 Tffei5j;^'(tWlR('3 <Jc)l^3i
isoft^300 ter.
331/31 31353
?sii-n^dct gr., f^., ? 3f?ter' 200 ter., 400 ter.,
600 ter., 80o' ter.
50 teg., 100 teg.,
300 teir.
100 teg./5 tê
Bitter
gly fe, ? teg
Bitter 100 tear., 200 teg.
50 teg. / 5te, ? teg
500 teg., 750 teg.,
1000 teg., 1500 tear.>1133/0101131?^ gr., te, ? Bitter
■ 50 teg., 150 ter.,
300 tear., 450 teg.
100 tear. / 5 f^tk
fitg^/Bittegr
giy te. ? teg
gr., te., ? ?B</g?tor 0.75 4g., 1 iar.
6.3 3gTI3i
531/37 537 ̂ ̂ 3lfer//fiSEf i/W
cte/tter /t te, ? goutelof 50 teg.
>tete 100 tear., 200 tear.,
gat/^B11qlte1 gi-, te, ? otw 2%
50 tear., 100 tegr.,
150 teBir.,
. 200 tear.
125 teg., 250 teg.
500,000 3rr/^
100,000 3g/^ '
ge'^tplolioftei
ft; ? ^g^ 3it? Bttte^f/
Btiilg^ettclol g^V ft; ? 3it7 Bjttter
Blt/^31'
B33?/ftBr gr., te, ? >t?gte
6.4 Tit'^3l3g^ 33lj3i
6.4.1 ljft?g>Stvit 331^3i
531/31 M 537 ̂ ̂ >/te ->135137
Bittegr 200 teg., 400 teg.
250 tear., 500 teg.
400 tear. / 5 tê
ft; ? goutcfyiof
?rte?ior
6.4.2 1ffef^(i'l5l3'1d 331^
6.4.2.1 tert
531/31 itoft 537 ̂ ̂ 3^^//teg >15te -335137
lssiatl[iim ft; ? Bitterr 250 tear., 400 teg.
gtte^aiggjc/ te., ? Bitterr 1=0 teg.
c'tte^;si?5r+ Btfttai?<ii+
5<tc.;i,?iggi
et/^1-^Sl?cl+ [atsloHSl^<n
150 tear.+ 200 teg.
+ 30 teg.
150 tegr.+ 300 tear.
15 tear., 30 tear.,
40 tear.
100 tear., 300 teg.
fS; ? Bittegr
f^stc^Stggj fe, ? Bitterr
35t 3t 33Tf3t
»IRft : 315HIRI7I 17
•'
j€^;si?5r + fe, ? ■ piMni- - 30' i+ 150 ft®..
"fe, ?
Esv;
' •’ ''-'i i- 300 f^;+
150
200 fkmt.
mmn
fqfsic^;gr55r+ ' ?.;1
Sj- •
?gr ̂ m
6.4.2.2
Aticidl
200’-,fimi^
600 ftcyf.to'ftjcroi fe, ?
200 tor;
so tor. / 5 tortô >rr5Br fe, ?
6.4.2.3
ggr ̂ A^siai
fs.. ? 200 tor., 400
fPm.
'■^*w
■:y^rS^ -
fe-, ? ' 250 tor.
100 tor., '■■■
400 tor./ 5 tor- -fe, ? '
'Vi-- fe, ? 200 tor. -
6.5 <iciij<ri
j . 6.5.1- ^ 44lj,ji[
,432^ 591 ^ a&Vl/st^'^ ->r9Hcn-
gnfertojgjiii^ ■r^ ?r., fe., ^ aittor’ 500 ftor.
3T., f^., ? torsrr 200 tor., 400 tor.
500 tor. /.loo- to-pocteror
6.5.2 tolfil
fe, ?
5923.^,^. a^w/:^tor .>t9aar
Btotor^ ^ go^creror 50'tor.
tertoof 3rr?tor9to fe, ? ?oi^9?rBr 200 tor.
6r?fe9<rt fe, ? ^oxtojoT 100 tor.'/; tor
6.5.3 l?toc>ft9^%n59T
6.5.3.1 5cnvt fcHi
597^ 59r ^ ® crtor/^'i^ .
?re<sratefe+Trr9to8n3rr5sr
^ OT^r «<^J''( ^7
vr., fe., ? tor9r 50 rtor. ■
•■ 150 torr. ^
40 tor. / tor
, 50 tor. ■ / 5 tor
‘>l][htni
pBi^rortteihJctMei ^}i4d
torrrr., to, ?
2.5 torr., 7.5 tor.rrr., to, ? arttorryigari9ifl°r ,.,
25 -.^. -arttorrwtorsrrarrgar , " rrr., to, ?
arttorr 300 torr.
300 tosr. / tor
sr., to., ,?
. to., g
c/tfitoato po53j5?ror
500 torrtj 25 torr,gr., to., ?am5kto+tortorarrarrgar
VllPid at 991^9! i'"*
150, 300 torr.arttorrto., ?
6.5.3.2 jrtft>c)R^r«
totosrargto.
591 ^ ̂ aiflq>(/sYti<9 vW59t/4t .TOerar
OTto ^^59Tg9t
250 torr. toajitorrto., g
6.5.4 aan 99^
■' y.
‘i
: ■•;
-.
,4^ -••'•••
'-■*1■'••: 4-.'
, t:
1: ■y
i't‘ "-1
THE.GAZETTE#.Indiai E|XR4§RblTjlARY .■ ,. .. [PART 11—SEC. 3(ij)] ■18
M -.4 -r.- .igaar
80 + MO pm.;
160+ 800
40 + 200 Pmt. / 5
■ ' ■' 'tlllhili- , ■ ■■-
■UiAe^M
fPu
*' \ \rv’ > fv ■ .
200 f^.fe, ?
WT; 7 -
7.1: c^'fc^ ^
mi ^ ̂ ^miipii .’raaar
sMcPii 300 - -350 ikw.udidimi ^Mkfkcp Nks ?r., fS-i ^
1 fkm.^itfenutfe, '?
■ ■ ' otlfct'tl:m., fe, 5
7.2:i
ill m Mm/'itM ^mi4^i mmi
10 fkm., -40 fkw.sdfkmAmoild
WT: 8 - ^ wRiliji ^1 R^iRT cjcll^^i
8.1:
mi M m ^mi4m M
<>i]tknirnifkiihi^si 50 ftw.?
■■-'■^^''-Tb-ft®';; 25’#iwr.,
50 Pm., 100 fkm.?
^ fep gmtefgf
8.2: liitlS'ili
100 fkmj fkfk
mi4m mi M m ci&mi/'^tM ^ Jimrni
gmiJcfSfor 0.5 Pm. '?
foi^ra' 3 ftfa -ijgj 3n^? .
PmPn^PiBr ^mAneisr 15 Pm.?
BiiPi'Ui 2 ftwr.
10 ter./ cn^Ter
50 ter./ crr^r^
jfppdPsi peu)<ti[S[?
3ztter "
goi^far
50 ter., 200 Pm.
500 -ter.
MmeP^tppm^
100 ter./ crrsTer
soorPm./ mmi
1000 ter./ 0Mci
?rr?ette Mkspm^ ?™J<tfrsr?
imptm 50 ter., 100 Pm.?
poujirtrsr 10 ter., 50 Pm.?
c^ingpr 100 ter.
100 terr./ 5 grst^? Japctim
BltfePlitre^dtrfrigg 250 ter.?
S.v<^h}iPiet got^for 250 ter. / 5 ter?
0]PiPt0 iiPis ^mAittlal 3 ter. / ter?
200 ter.i^stterte eiPslWiips poS^Iof?
1 ®r.
19
qRai.fi ; sTOivi^n'[«nn 11-^ 3(ii):] ;
5000 ^-1.
m-cmrafSi^ ?
2 fkm., 5 §m.-i ■ -.diJfetdJt
# rflmdol
50 tear.
100 ftjiir. /
Bitfkm
?s^m
r,'j
?■ ■
2.5 fW.
50 /^./ fWk
sitlkm
?
10 to.
gou}i<?[3r
?■ 30 fto./ 5 to'
? 50 -/to.
?S^M
5ou}cf?[or
?
fcfoi^irffeor 'He'pti
10 ffen.
? 1 fto./ f^f/^
fysrfsPF^ 1
t6t ^
/'Sfp 150 Pm., 450 Pm. graef
500 Pm.
gou/q^rSf
gtruJcfSfof. tpiujalcot '
?^tp(q/(^cr( 20 Pm. grac?
1 gr./2 Prlcim^
poxjJqSfof
Mt^hdlPioT ?
.Jou/cfSfSf
?3<ig‘pla‘Pi‘*tliitf 200 Pm.pouiq?[or
?toff 50 Pm.
100'/to.;' 400 Pm. 'PtPm ,
■SUctUlcdPtl^ ?
? 2 to.sit/to
?
8.3: fto CISJT
.'mar
5 /to.
20 to., 25 to!
gs/fto' 3ik
60 Pm.
10 Pm.. 20 to.
M ?gr
3dfePa
fev ?4s/toto gou}cf?ror
— PtPm'
■Msre/to ^ ̂ . 3?/fto
^qqetal
Mddl^.' 10 Pm., 'ai/tor
■ ■■ 4 Pm., 8 Pm. ,
2 /to./ PiPi ■
iiillkm
. 'pou/d^foT
' fev'l ■■ . ' 3ifsr^s^^_'< 2 to./5 /to ‘-I'
/to
^nftci <i5t ’it
1 /to mm
100 Pm.
pou/cKfoT
3l//to■ /toSR^' '
11^
5gr ^ ̂
3im: 9
-tdridf
HtU^
1.25 Pm., 2.5 Pm.
100 /to.-l; 10
250 /to.-h 25 Pm.
100 /to.-h 25 Pm.
uiPm
/^., ?
^^tshi+ipil^sht ~ i>ll[ct<uim., fS: n
2 /to.■ 3i//to. Tir., /^., ? ^
B[ggldct/<!T?S
.A .. ^
■ the GAZETTE OF INbiA.: EX^iji]ai&iTOi-20
#.■u -'?SFa iSI&EI ticiijiii
10.1:
niiUni
Mmm
mmpAmm3n?a[-- -
r-fkw7/-fkfk-•> i ■:
60 f^RZT; MkS?tei-3lPr{S[-i^-■hav' ! /
- TOfe-^rar--/i •j
•--
25 - —
Hgfe ^mm)/ Mk i
T ftw.-,;-5-ftwT- ■—j
so ^rar. '3n^/-ftfe-~4
t
•/ ,
Mks gr-, t^,:g - 1
SUigtsi jctn^ct ■ f^., ^ -rr ■:
g7., fe, g ;
^
lo'ikw:-
10.2: ipnf^ gR^-cncft-gq^
ggr ^
jmm..-- L
1000 311^/
5000 3n^/ ftfer- -
fe, ? tsik^rsf
fe, g go^fof 10 f^;/wd'iietirdul’n pstteiof 10 ftar./ ftftr
-- -fe,-g dillcl’Hi 5 ft®.
C^]<tillJl[icsl ~. • gm^cfgfgf ■ 40 ft®., 60 ft®.
' -1?:'©
WTT : 11 - ^ ^aTT,;^|vi*||
11.1: 'ctlW ftwm
. M 4ggr ^
.40
.70 '
’ <cnT^
gi^v. fe, g ?5uk?for 'v :';io%
g^v fe, g ga^fof
6%
ff gouksfof 1'^ r:
fe, ?icit-CLxl) ]li>A6%
d[ef>)[m<n U Sfe, ?
11.2: v?irqft ^
i ggf ^ ̂M
, :. 3.5%v;
55tRm
591^'
jmmUeiQ^lkk fe, ? 5ovi?c[?ft- 5%, 20 %M'UilkPlid fS; ^ lo^Sfof
‘ftg? g™
<ftg? CT '“'
wmkm
; ^Ph’^^hdpr ^fte?; "J:
njjgnp 13JJ
fe, ?
%., ? p<k<fsr5t
3^
*^5^ ftr ■cfTof® fe., ? .C-y
goofeR
^ : 12 -
12.1:
^ ->raHar
'iS
■i.-
21
}
r-T.'
uFUdlUd AlelPuli
Ms
W
75 ^m., i(»i#raT.,
350 ikm.
0
o 37., .fe, 5 ajWefJjf
i [hletHljJi fe, g azt%5?r ■ 30 . 60 tof.
I MuilRcl . MeMm WlSiii
?s^m:
0.5
5 ■
37., fe, ?
i .. .^//,.?. ■
5.
' ■ sr:, Mr? ■ ■■ -:10-#fW;,-
20-f^r
mmt
22.2rvfai!TF(1^i^‘ .7
ft -. ;■ .-4 •■■ ' ^ k:VsMx^ "J~'•fw
25 ikm.,so Mir.
1 Mm./ Mk
kihMci
\
37., fe, ? pox^^ior ■
i.; i^Y'W.nPm 7^1 ^fy, f/
rmllkshiid- '■'■irmai: '?
I2j2: xjfeRgPra; cjciig^ti
;=:4x.-r.-—^-..-.' 597^ ' jmrm
T:Cf . !vf
:~7>' loor^;2Dp ter.
■50 ter.7 'f^r3 ter
30 ter., 60 tezr.
ST., ;
^axj{c[?Tm
;n i; ' ' -‘‘^Wpii
.-K.,
■i - ■ ?- iou?5?fsr 5 ter7' ter
ui-nMct 10 Mm./ tergoujcjffor?
[ei’imlvm M ? ■ 1%, 2%
250 ter.
100 ter./ ter
sitter
^ct^rm
uMdlJtl^S
?
40 ter.; 80 ter.
2.5 ter./ ter
srtf^ •
gCT^igrfe, ?terrte
12.3:
m M mr n&m/M^<{<«/«r .ir^erar
2.5 ter.,
5 ter.sitter3r., M ?■rmtfkftrm’
50 ter.,
100' Mm.mtMri, . 37., fe, ?U^oileilm ,
??r
. 2.5 ter;,'5 ter; ■
1.25 ter./ ter
mifkm,.l.
•i 'fc,'-.
f
ucniciiikci'kfetl/s. .
g». .->1
cilniiik'mikfkrm
I i'f
gou!cr?i^
sitterf*-'
■'!t
25'ter.,
50 ter.'■4-
■ 4.'’ - ■
250 tef,sitter3r., fe, ?tei>T«slSl
^11^
Siifedit
jiT^ ftteir sitterr aitir
cgS'^oi' ^
5 teir.,10 ter.
10 ter., 20 teir.
10 ter.,20 ter.
te, ?m$<efkP[Sf
mtMm ? 50 ter./ '5 ter
SllPld r^t ^ cjciigiji
12.5,
sitterr3r.; te, ? 25 ter.
‘22 THE GAZETTE OF INDIA : EXTRAORDINARY [Part 11—SEc./3(ii')1
-. - .I ■ ■
X: gcjquit) ̂ ?12.4
I'v/-'
M
jrmdi '
[sufTcpifloi
0.25J/%r'.' ;
0.25
0,05.
\
fe, $
GfecKH
. i
4. .V? :::-"'5o f^./
et»>§l<ieiJ<lgs
i^'?r •:‘.x !?75?-i
AO-Pm-/ Pkfk'-7\ni'p ■*)
n :
'■ .-p. ^.
• I •
12.^:
■.{
■ ‘2
nm ^ m /-WeRiT
75 /
100 ikm.,
350 Pm. ,
1000 srr^ /
5000 37R^ /; -pify
750,000
15, 00,000 .
Mv.
, "500,000
10,00,000 sRif; / ftrfe
Upiciiiel ^[clPiPi^
■ .wtfemi . .-
fS; . ? ?Sifefgf.^HiPn. fil[s^>n
fe, ?•U
?
^nWcT ^ Ttf. ^ ̂
12.6 gcni^
■ UdidU-iPai fe, g s fir-gr.,10 firar.
: 13 - i^ieMll^chd gcfi^ (^chH)
13.1: ~
. ^ ̂ wr
oil^acAat Sfti •
13.2: ljfe$4!|cAicj
ggr ^ ̂
irm
Jmeldl
fe, g
2%
gm/etf
U^invetlJl'i
■ PimmM^MkiPf
. ‘iwjilgs E^o^SfoT
Pi^]<nt^Pi<n+ iPf^
vtfiidlkfsmtfkar
filedi 7[mifkmfS[Si
mmifS; ?■
gfy fe, g
6^ 5%
sffe 0.5%
37., fe., ?
0.5%
37., fe, ?. otPmkos 5 Pm., 500 / 3ff,37;, f^., ^
37., f^., g
ofk'Smstkss
13.3: gan gcfif^
5%-'
1%
^l/-37
fkc:iPisikPf
gr^atfWsfe ^., 'f^.,-q S^£ snWaJcff - 0.05%
W<!ii<Hi$<n 37;,- crfjfor •
' ■ ' ' 13.4: STffgTiTfe gcnsit
. '. ' ggi/^TR...
Pi^ atmaws
. , gg7^ ^ dilm/'^f^ ist^
Mmm37., fe, g.
13.5: tmr
23
, '■ ['iTlJI lI-TsFTS 3(ii)] <be =,g\i
, , ■
2i5aarM■ 1
\,
5%.izr, fe, ?'cjsra are
0.1-2%
ST^smfm ?
gr„ fS; ^3e(rererft^
5%.W:, fsl., ?
gar ^ TO
5it?fsr
13.6^
jq^erai '
I !■ 25 %??., fe, ?I ' ^gjjfPfg '
.M,
. 5%5^
fe, ?, , , T23?srte • 1%, 5%•at?rsr
iIFT: 14 -
; ailiiarat^ c;cii5<4i14.1
ggr ^ Aiaai
(fm^
1%SiffiCT gk
sma gk
'321® cpI ^
fe, ^
4%
fe, ?fe/ciN}?^
1%
fe., ?g?.[?lipWl'gg'
14.2: ils'^l'ploiWiii *{l[s<u
M. ^ Wl crf?^/sf^ 'pW M4eim
?argdl^ 100% s^/sftp 250%
g^/cf??re%?f=rfe, ?;
'■•' ■ 3pButefcffe,iMkim sfTgrttg
3irategf?^4^.4fes'‘~‘~’'
^3[c^3ji?^ .orratsciT^
ipo.fe®.
60% s^/cfl {smffksi
- 280 Pm. / WgfJ
5-8 4ir. smtfksr ^
100-250 .firfer
500-600 tor. / Mk
70%
^20 ft®. / ftftJ
poxj}ti?[orfS; ^
smfku ^r^isr .
fe, ?^TSIC^SH^Sl 3Il'’jIfJvilci
Si.
fs... ?
■r-'S fmjjtrersr
60% gw^/Eff
cpctp,
=292 .ft®./ ftftj,. 76%
gyo ft®./ ftftJ
V
gnfeftsiteg
f^-, ?
ITPI; 15' tisn ^{fci'cif^tjj
. I5.i: :
^ m wi-attm/tm
J-: ■- '' ctr-
jiijaar
•Mgaig®
,®., fe, ?
fsn-TS Oetplfe 70-'
ft'cptre®., fe, g -
gl., fe., cT V,
20% ^ to
5% ^ to
^J
HI., fe, ?
0.5%,
1%gi.,' fe, ■?
6%[?forgr., ft*.,
®., fe, ?
glggftg? ii\ctil[?S
iiiftgft smlt^
5%, 10%
■*. ■
24: ■ ■ THE GAgTTE^F ; mM.QmMM .{P/VRTII—Sec. 3,(,i:i>1 •.
W
. ' M ’ ■■
mmi'X
30 % s^/g^ zmm
‘feMsr # a/rfidi? <p3r #
[377^.^. sn-en? wj
34 tp?7
Hfe^?rBr cpt 100
HTSf grated cpai^
^ 3776717 Wj
fhei^s '^LCl
mjg7
,. '...W
■ i1 i'' |37'7.li} ■T
?7., fe, ? 77?e^?7oT
^c^cticifesigs
Trmic^iicii
? .
^•, fe., ?
TTte^fTsr 2%
^ ftn? ste^fTcf
^ R
’im : W -^^f^cHT ;c«<'
ggr ^ qsr a-Rm/'itd^ tdfif
wmi
gout^for
• ̂Ifeini
^^Hl'ltlpS w., fe, ? ! ■ 10 ft®./ ftft
j_ . 40 ft®.
25'ft®., ■
50 ft®.
10%, 20%
~ 25 ft®.
^T., fe., ^ ftft®
<d[iiaic](n
li-Ujailetdclat
^■, fe, ? goufeffff
?T., fe, gr ■ ftft®
17 - ^cii^ar
17.1: IJciRi-s ?fan 37® TffeHTTTTT
HI ^ H' ̂ ciSmr/^fH
175®®
uc^fk^rm
6l^^l'mi?s+ Hlkl^RPi
TTiftsST®'■
. 37., f^., ?
37ftyiu7|®
W/c/soJ
37., fe,' g
. ' 37.,, fe.,. or
- -.-— ,,
Tnftcl ^ Ilf ,
10 ft®., 20 ft®., 40
25 ft®. / ftfef
^orduK^lel
’Mfifksi 1 1 gCT^ft 40 ft®.37., fe, g■■ STtfcT® 20 ft®.
17.2: tife^ftfecRT gcirflrt'
557 ^ ̂
^dtfkilisftiJRgft ■
35e7®
. 10 ft®.
1 ft377. / ftft
. 10. ftwr.
s ft377. / 5 ftft
5 ft®. / ft%
10 ft®., ■' ft®.
5 ft“J7./ 5 ftft
25 ft®.-/ ^
37., f^., ?
ftlTT
^][kniddmt 37., fe, 5 ft7>7
gotjcfgfcf
aitfcT®
7?ft<tt77 37?7 ftlTT
gS^fof
sftsTTftor 37., f^., ^
ft., ? 'v'"' 4 ft®., 8 ft®.
2 ft®./ ftft
I ft®./ ftft
ft®
poftwr®
■••V
ir--'
[tIFI ll--®n5 3(ii)] 25TO ̂ ; TO’-Jin
17.3:
?5r w ct’Uf’i/ sY<l*?M mem
?nf5lei tl?t ■>1^ qqi^ili’
5.p^f^ ^(k[h[k<t> ifies
; s.tofe
fe, ? 400 fim.
17.4: cjcll^iji
mi ^ m ciifl<pi/sYdt?mi^m mem
10 fk’ui.
10 ter./ ter
3rf/(^?rr’
?4ufir?ror3T.,eifs^ecihi^s
^f(WI
jSoijJcffrof
10 f>mn.
20 firm./ te-firr., fS; 5,enikir^m c^prjer ate^
17.5:
aar ^ w eiitm/^i^miiai mem
5 ter.terar’ wv/teiSar., fe., g
m, fe., ? ■rlo^rtr$i-maieii
17.6: §5tra ferj ^cflfJIT
17.6.1 :g®M Plvjicfltr^ITJT ?iaDT
aar ^ ®r ci&m/it^^MMlaai/ar iiartctr
scjaitTr.' 13.5 m./ uer.
nih^jr nertms: 2.6 ■
m./ uei.
ikilirm wetkr^: i.s 4rr./
era.Trlc^froT te arnsTar.i ^sfreer ffera^fror Tfe" srMfeaw Trr?^ ^r?mie+ •■
2.9 m./ner.
2ooter, 500 ter, 1000 tea,
3?' fkn wise
^n^.il. ^ oaerr? a7j
17.6.2
I . mi M m wSm/tf^
- ijiifira tj)t aarfat
M ?a^aatffai
20 f^ir IS fterftrwHT., fe., ^fiiiip 7?^
1TFT: 18 ■ ?TRf^, 3Rf ^aifTlf 3ik aif f^«Tc8
18.1: xprf^jaet fmta aik
mi ^ ̂ U,^.ClClLMt
0.5 terr.
4 terr./
artfeaf
fax^mfe, ?iaOTftaiuffe
6l^^]ct>](Siitei «J/sa-a
mtMu
100 .ten. / te^$ax^TSf5T., fS; ?
40 fkm./ Mk
5 tear.,
10 ten.,
20 ten.
pouia^rsffe, ?f^smei i^o{lnM<n
arttennr., fe, ?
I8.2:
aar ^ tw uactdfaai^ar
40 tear.
HsnsrJ
25 ten./ f^rfe frtfttek
TrrorJ ,
nr., f^., ^ poul Iff tBT
18.3: telaa)
fcjqS.^ll3 4^
26 THE GAZETTE OF INDIA : EXTRAORDINARY [PART 11—Sec. 3(ii)]
18.3.1:
ggr cl°i ̂ aflm/ iraridl
0.03 Pm. + 0.15 ter.
r+
w., f^., ? . aitter 0.035 terr.+ i.o. Pm.spwfhP^iilcj
e}q?oiIto)i^|e; plJ{]zlat
dcilciico^i^lci PPtptoi)
ERH]<n tefter 317^^ ? 377^^
18.3.2: vlMchyui
ggr ̂
rppR ^■, fS; ?
18.3.3:
gar ^ g7 ysraar
'0i<!isi'n ^■, fe, ?
18.4:
gar^ar gar ^ mr ccSm/'it^ F yasar
0.01 ter.
0.05 ter.
yr., fe,- ? artftraf
18.5: yaaa ga^
18.5.1: 3tty 3}^ T{^ ̂ 1^
gar ^ ̂gai/ar'
. yasar
Plfet^ 2.5 ter.,
5 terr.
y?., fe, ? arftef(^m^nips
poster 5Su[a?ror
f -itlc^ctd]
{el<^ / Uai'Uuu
yr., fe, ? pox^iof 40 377#^ / ter
yr., fe, ? pn^ra' 40 377^ / ter
ateyteior yr., fe, ? ^HfcPn 500 ter.
ante a5I ti^ garfaf
ftfttew pagte 30: 70
poterar yr., fe, ? pButefoT 40 srrrf^/ ter
48.5.2 iji^M'iPic!1Ri<i<4i 5einjt ^^cHi aa^at
gar/ar M
yarsar
? ?30?a?(or 1 tejr./ tey
yrite t^I aarfat
25: yr., fe., g pBuftf?pr 100 ter
18.6 artaelyFr ^aa^rry
gar ^ ̂ aifer/g'te'gar/ar’
yqerai
50 ter.,
100 ter.
itcilPt^ arpijd
arlter
18.7
gar^ar' gar ^ w dilm/'iMw
ya^
tej^oT ^tea yr.', f^., ? 5 ter., •
10 Pm.ter/^rftate ^., fe., ? al/erar 5 Pm.
27TOi ̂ : 3raiw>i[«)m II-^®3 3(ii)]
18.8 ®JT5^1?3 afrf <c|^«T
mMm c[&^/itM ̂M mcicu
5 fkrni.,
10 Pm.
oilfk^VI., fe, ?
50
VI., fS; ■? ■’ odfeini 100 ^
8 Pm. / 5. P[fk3u^\(k<n
3Tm: 19 '{VlMf?l'(l{m
19,1: ^5iPra> TJute”
591 ^ w ^ y^dciiMS&vftpif
siftof iMfecf
pou}(t?for5r., fe, .?.
19.2: ^
TraaarsMiPii 557
300 55§?T^5?ra'fe, ?
10 ^5i^5?iorVI., fS., ^
•iJ/etdcloc ucflt-oiv ^®Pf
250 3TI^ 500 311#^5<^5?for37./ fe, ?
10,000 377^fi^9?f37fe, ? .
JftiH ?'KjloiJ''<?l]ft<'( 150 37l!^^- /ftfe5i^5?7=737.,' fe, ?
19.3:
19.3.1: uf^tcR^cT ^ 3iR|3«13T
557 5P7 t7^te7/^fi^ t’Y'tf 353777MsttvPPli
?^rsr37., fe, ?
?ite7sr37., fe, ?
?<^5?75r37., fe., ?
, ■■■ gj^Tgf37., fe, ?
37773 3tfe757375^ft77
dft7«3 UcHj)
77^5^773737., fS; ?
19.3.2: ctjIcRl 57t 1^
557 ^ ̂ cC&^/'dt^ ■
?ot5?73737
353777
aflwPm
., fe, g
37., fe., ?
t&27 dfe?73
5o?c7?7o7^2377 dvm?s
l^^cFfe Xif^) 3ik TStfel^^!^3775: 20 -
557 ^ ̂ cCft^/'st^ 353777
10 Pm. /
15 Pm.,
0.5 Pm./ ftrfer
60 Pm.,
1 #737./ ftfe
.50 f^./ Wk
sitvPpa
5ok?73fi?., ?9757775^
sdfkvt
fS; ?PrvtT^tw^im
37?fc757
' ?ote7B7fe, ?■muPdlPdcrtJil^oj
7757fl3753 53?3gg ?3t5?75ffe, ?
28 THE GAZETTE OF INDIA : EXTRAORDINARY
[Part II—Sec. Sdni
^■, fe, g 2 ikm./ Mk
’ini : 21 - aftTOcRtciff^IcBa ftfSrfJJRtuf
21.1: Tfwis
gar kk ^ggz^
ygirfctr
fe, ? '^/ sikmskss 0.4%, 1%iiiukeiUittm
52., fe, 5 §t5/3iT?fgfS3[oe- 0.3%
ofogTOgffer 52., fe, ?
52., fe, ?
5^2 0.3%ft<p(oi(o(Ie( I^2 1%nllhsk fe, ^ 5^2 0.6%\iic>Pqcirf((ps
kl[kn-H 52., fe, ? 5^ 10%, 20%
21.2: tpjtg
ggl^
msm^seUnleii^
52., fS., ^ 5^5 0.1%
52., tg., 5 5?5 1%
21.3: ~<Hlci)cl
^ kA m wSm/'sf^ggi^
5geJdl
^?;icpoi
52., fe, ?
0.5%
: I'iid'lfoi) tian ggrg^
ggr cn!ter/^ijg~^
21.4
532^52
aUtCMlcu-ni^s fs., ?
250 ^r.4cicr«l«!ef miUeiklfS
? 0.25%,
0.5%
fterferOTTgof fe, ? 2%,
4%
52., fe, ? S^f 0.25%,
0.5%,
21.5: —
332 ^ ̂
§?5/3iT332g3fer
czhi$tn 53c2sr52., fe, ^
52., fe., 3
52., fe, 5
1%
I^2fksirUelPPiPTSf 2%
5%21.6: 3l1wf^ ^
■ 5uf3?2o2
332^ ■ «
33332
•?
. 2%
: 22 - 3TlR5!irilRi>H 3annm
22.1: aftf^retRm
332^'
52., fe,
332 ^ ̂fkstrsm uisitkcra?s[ mmi
'^kfkm 0.125 f^.
291TO ̂ : 3rai*-wn
-r Cfi
0.2 tor./ tor
200 1km.ktfkmsrrtotek ?
5 3rr^ / tor,
10 3rr^/ torito?rorfe., ?sfmfktfkoT
100 ̂oil !k til(kuMidci
22.2:
rraeicrr
2.5 to.
0.5 to./ /tor
storJiT
gtorBTfe, ?iitJidifkm Hto
?nto cfit ■nt tj^rnpri
10 to.ktfkmm?wfkftiw
4 to./ /^/^ar., /^., ?lkci[ksii<^}<n
?tm: 23 - -dirjf^Rrfr
a^rtcirM.5®^
4 er^rsrar^o^iiiakllkni^
?
ilFT : 24 -
toaito ^24.1:
^ Hk m crSm/ktk^ ^ WeldlM
25 to., 50 fkm.,
100 to.
25 to./5 /tor
25 to./ /tor
5 to./ /tor
tor®
g5r/torrr?r?sr fkmm., fs., ?
■ Z^-, gtatotor
Tirto nt cjcti^ni
5 /tor., 10 fkm.kffkm3del<ni^i'll?‘n ?
^ ftoafr^ rigrra 3®?®24.2:
g® ^ ®r afl®r/^f^
ai//tor
24.2.1:
iraaar
M441?® 25 to.m., fe, ?cfto^ra^
20 to.■retj^u/irticKl ®., fS; ?
sifg/wil 25 fkm., 75 to.rtp&
oijfattl®- fe. g . , ——
9^ 2.2: gratoR ttoan^ A ^4T5®
^ ®r vKk
oilfcitii
g
agctar
300 /tor. '4®^
ferik^ g’W/cfe'
?nfto ^’T?
200 fkm.,
500 /tor.tor®
®., ft; gw]/^<CT toaite
30 THE GAZETTE OF INDIA ; EXTRAORDINARY
[PartII—SEC.3(ii)1
if\ 24.3: 31PT yqiRT
ggf ̂ ̂ ^
T/leidf
VcW^itePI 0.25 Pm.,
0.5 Pm.
ST., fe, 5 ^feprt
2 ftt.,
5,ftw.
fe, ?
24.4: t%TOTT;^ tr^ ̂ fjiftT
I I ggr ^ ~|
?nWof nit Tif
mmm
'tc^dlkac<H
W., fe, 5
• 20
’^1:25- cli^ cn^gcTT^Jlt
25.1: gcfT^
ggr ̂ ̂Mtiui4m
VUeidl(k<P(nlPiSiii^]t!t
^ulPtuMd ®r., fe, ? 50
250i^ijfl / gti^ .
100 Pm., •
200 fW.,
400 Pmi.
2 Pm., 4 ft®.
2 ft®./5 ftft
100 ̂ / gft-
w., fe, 5
ftw
rfef^pisrfer He<^ ?2., fsl., ?.
go^e^ffof
^nftcT ii>t ^cn^ui
gf-, fe, ? 20 ̂ /afeg gft-
25.2: ~
siffem
HI
mmt
■Plfsol fe, ? 10 ft®.
15 ft®./5 ftft
30 ft®.
ft?7
i^njiPispTH gf-, fe, f ^\fom
26 - Pte^, cfsn
XT
26.1: aiRcI
PPI^ ^ H m d'Rtpi/ifH
memg2., fe., g gra^ 3?ft Titmm
26.2: ~ '
3t?^ V? ^ sfren?
PPI^’
^uJtrer^
waargg-, fe, ? 5% snMdPi, 10%, 15%atft2w
ga?agg Hfta 32., ?
5%+ 0.9%
aYrf/et ^eflggr
GBre2 jlrtiScj
32., fe, g
0.9%fe, ?
c^ies Hi^<n
gterf^rwa gafagg
ftg? eJtflid
fe, ?
32., fe, g
n.2%
3n^ »# ^ aaemr g?
3n^ tfl ^ aacfi? if?
32., fe, a 5<^p?ra
32., fe. gojq^fof
26.3:
^ fee ingff
^uj<t?f3r
Wridf
i ftfe, 5 ftft. 10 ftfiir32., fe, g
[im 11-®M 3(ii)] 31
6^^
WT: 27 - RdlRlH 3ik .
mi M m wSm/^tMMmifyi UHdcll
100 f^m., 500 ftm.^■, fe, ? ^’dfkm6ftis
250 Pmi., -soo firm.^Tim ipraM? gr., fe, g
m wmm sjMkm
^ z ̂ snoR
W
52., fe, ?
50 PmI.^IfePn■gf., fe, ?[krp][i.<ni'Hl$^
'iillciui 25 Pm.gf., fS; nmuPdlwiftsi
5 PpSl.g2., fe, ^Pftetlcld
mnPiof ■ 100 Pm.52., fe., ? ■
5000 322if%
50000 322i-.^^ 100000 321f&5^g2., fe, 5PiziPm U
■ 50000 .322^/ PlfP
PiziPm ^
; moi)$fc^U^del^
0.25 Pm., 1 PPir.f&5^
girfijef 2^^ fit
52., fe., ?
100 Pm./ Prfk ^ io
2'a5-^?1^5?2BT52., fe, ? Jf^fe?RW acj<p|o}d
3T^-2
SgiW-1
ra p)WR> ^ grafira ^ 3Tt^ cBT f5m2R/g^«w 3n^ gn litwrf .
[%I 2 (^) 5,7,8,9,15
1.
cf5T ^ sfk w :
f!tqgH cftiT^ cf5T ■^, 2Tl^ cf5\t--^ :
321^ Praw gM affg ar^ffifer et^ ^ ar^giR g#f9rgi :
■ sftEffgf arpTT gfgsjtcp sftg (jrfiT ^ :
-dcqi^/3TT2ITd ^
f?rf»f ^ WT/^ 3TTf^) :
^ c[5T 3TT^ (lOXTgT/iOOTJgr/lft.cft./ 2Rcft. / lOR^. /5TITH/103nH Sflfq):
RPi'Rfil ^ 'vJMdlg :
f^racPT/g^OT ^ ^ ^ ̂ :
cif3TH i
i
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
3?Tf?>^ f?tna3^ :
WFf :
^ :
:
cTT^ :
[Part II—Sec. 3(ii)]THE GAZETTE OF INDIA : EXTRAORDINARY32
■315^-2
wm-2 ..
RPiRRiiit cjn ^
(1^16^)
^ ̂ sfk'WT :1.
cpT ^ 3fF? w, cf^rt t:2.
'^r
arj^jpid RiPlRlci/
^ ait^fEj cf)T
^ cItIR50TI0
RPiRIa afk vj'tinil
Tpicfj cfir
3nq>K
(1) (2) (3) (4) (5)
“~2S~ZnS25CK'3Tg^|txRT IqHmid
Tq RPiRd ftprfj^frRTT
RTJT -qt/anriTf^ l^rMcmr
arf^WR ■gsETirT cf?PT?T
(t^. aftr T?f|d)
R)TT^
trr ^0(f.^.Tlfld)
(^0) (^0) (srfE^qpm) 3fk
(^0)
(6) (7) (8) (9) (10) (11)
feq^I5T_:-sPJT ^ -qf f^lPiRRl ^ fclPlHfdl RiT ^ Wdf^ld fctnrT ^ifTW I
dM'ddd if ^ 71^ '^Hchl^l if^ TIcifcR' stH affT i?r?c[RT % ^ 3ik TCT t I
d ■gTdTSNwt :
WET :
qm :
:
■RRti ^ : srervRni .33
3T^-2-
WT-3
^ afr^w :
f^WT citTrft ^ ̂ afk w, ^ t:
W ̂ f%HT^ v}rtldd/3Mlcf aik fcl^ ^ sff7 : —
w?Dft-3r
1.
2.
3.
3I
RRRRl ^
JRi'T Wira=T/3TPTra cfJT ^
{3lfO/fii.3n./f^O)
•^aft
f?mT^ fcWI^ fimif
(1) (2) (3) (4) (5) (6) (7) (8) . (9)
’Eftaft Rmr^^ ■ ^ fcmi#
(10) (11) (12) (13) (14)
33rn>ft-3n
^44 nRledlRd-
STOtf^ftffitcT 4f
^mfiT f%IJ
^ artgi
aft^ c(5T
VjCMiq'l/Oil^ld ^ 'W'^
(f^.UT./^.)
#fr51'Tfaft
fcmr^f^mr#. fipnf
aiPT
(6) (7) (8)(4) (5)(2) (3)(1)
Encja^ ,
(fki4t f^ar# alaft fitarfla?cft
fctai^
(12) •(13)(11)(9) (10)
34 the gazette of INDIA : EXTRAORDINARY
[Part II—sec, 3(ii)l
gp
SL'* ^
^ I
WH :
cn^a :
«■
^ ;
T^^TR :
3T^^-2
^ :5rw-4
[■^ 2(2) M]
f^P
fen? sfwrf
iRfrr cpr ^ ;1.
f^^^PTl^/3?WrcT^ cfji 3jf^ ;
3TWgr f%4^ jrr^prRjff gRT grarfK
2.
3.
4. T 3jk arjffrfef ^ 3tjhr ;
jTflrasm SIJS, ^ 3#, ^ ̂ ̂ .
^ gW 3fk arf^RjcRT cfft :
5.
6.
STflmKR ^
^ 3T^ jjgrf ;
7.
dl'3'W ;
8.
9. ^^wr/3TRRT ^ cfft Tnikj ;
^ ̂ JRtTTfcfcT rTT^kj :10.
11. ^^TTg^/STRRT ^ «ig cfR^ ^
cpRDT :
12. ^ ̂ ̂HflcT f?r0^ 5 cT^ .
er^cTRf^ .
2013o^3TEft^"^3^-^,^^
3TW?r 3TTWcHt7||f
^ Bfg cfR^ ^
^gr
gj)f 3?RT RPJcPT?) ;
13.
14.
̂ ̂ ̂STHT^rf^ gflf ^
^ ̂ ̂ ̂ ̂ arraftcf t \
15.
^SJR
^FT :cfllte ;
WTFT :
[*im ll--0^3(ii)] »?Rcl ̂ TTSm ; STffltlRq 35
JfWT-5
[^ 2(x) 24,25,26
^ ̂ 3?t7 W :1.
f?rwT cfMt M ̂ 3ft? wr, ̂ ̂ t:2.
?n?Dft-3T
^ SIICPKgio^fo 3?ggr gr gig (RRRRi
31^ isggft <5'iicu gg
3M?r Pig^i)|
SRI
^jggRf^^ git gitgg.
(iiit.gftg)
Slf^chdH jcgiy
^^tgg (i#. 3ik gR
JRW) (^) gf|g)
(^)
(1) (2) (3) (4) (5) (6)
^ filPiRd RRRRdi
g>g git g^ angiffm RRRRigi
^fTT^-STT
c!?! GTTcJJRdfMid gg gig (RRRR
3tW gggft 7|^ig) gg
giogo afrgflr Rggig
jgftlcpiRi)) gRi
ajHiftd gfSwR
gsggRR^
^tgg (tiit.gfig)
sifsiggig (t.ii. afR
gR gl%ci)
ireg) M M
(1) (2) (3) (4) (5) (6)
^ 31 j-jjRid ftPiRRi
gg RRRg RRRRgi
gig g>t g^ aggiRg RRRRi
^utptmr :-wj g5f gf RPiRRr gtg^ ̂f, RPigidi gg gtg ̂ ggRra ftjgr gmfgr i
^g'iW ̂ ̂ gf gggggt ing sft? f^?gm ̂ ̂ afR' ̂ t I
giRt^ ■g^diSRggrf
gpT
gggjg
WH :
grtte:
J
36 rHE GAZE1TE OF INDIA : EXTRAORDINARY
[Part 11—Sec. 3(ii)i
MINISTRY OF CHEMICALS AND FERTILIZERS
(Department of Pharmaceuticals)
ORDER
New Delhi, the 15th May, 2013
2) ,rr" ■'’9 “-SMPrte com™,) order 20,3( ) come mto force on the date of its publication in the Official Gazette
2. Definitions.- (l) in this Order, unless the
A
context otherwise requires
ct, 1955, (10 of
or omitted to be
,-
(a) "Act" means the Essential Commodity Act,
1955 (10 of 1955);
pr!,dSTn7ud^7“'eX‘'|^^^^^^^^ biological or plant
as distinct from thoseTothSl^s;'^"' °^ber feature that identifies one seller's drug
° <» forme, mcordance w,.h .ho
(f) "distributor"
or sale of drugs, whether as g wholesaler or
of drugs and includes an agent or a stockistfor dr„;;or ̂ riToaTor"
(g) "existing manufacturer"
Gazette.
means manufacturer existing on the date of publication of this order i
in the Official
(h) "Form" i
(i) "formulation" means a medicine processed out of
p armaceutical aids, for internal or external use for
disease and, but shall not include -
means a form specified in the Second Schedule;
or containmg one or more drugs with or without use of any
or in the diagnosis, treatment, mitigation or prevention of
any bonafide Ayurvedic (including Sidha)
Unani (Tibb) systems ofor
(i) any medicine included in
medicines;
(») an, medicine Included In the Homeopethic svc.em of medicine-
pharmaceutical Ingredient contained In the formuladom Whlt^ name or the name of the active
(k) "Government" means the Central Government;
and
name;
“Sit 1?;^^ means bringing a drug into India from a place
(m) "local taxes" means any tax or levy (except exci
the Government or the State Government
manufacturer or his agent or dealer;
imgsrSrrt;on°orsareK^^^^^^ manufactures, i
or
imports and markets
or
percentage of price to" retailer;
to a drug collected or obtained by the Government
as
['Jm II-'!gTS3(ii)] HRcI ̂ 37
(r) "maximum retail price" means the ceiling price or the retail price plus local taxes and duties as applicable, at
which the drug shall be sold to the ultimate consumer and where such price is mentioned on the pack;
(s) "moving annual turnover" in a particular rnonth means cumulative sales-value for twelve months in domestic
market, where the sales value of that month is added and the corresponding sales of the same month in the
previous year are subtracted;
(t) "National List of Essential Medicines" means National List of Essential Medicines, 2011 published by the
Ministry of Health and Family Welfare as updated or revised from time to time and included in the first schedule
of this order by the Government through a notification in the Official Gazette;
(u) "new drug" for the purposes of this Order shall mean a formulation launched by an existing manufacturer of
a drug of specified dosages and strengths as listed in the National List of Essential Medicines by combining the
drug with another drug either listed or not listed in the National List of Essential Medicines or a formulation
launched by changing the strength or dosages or both of the same drug of specified dosages and strengths as
listed in the National List of Essential Medicines,
(v) "non-scheduled formulation" means a formulation, the dosage and strengths of which are not specified in the
First Schedule;
(w) "pharmacoeconomics" means a scientific discipline that compares the therapeutic value of one
pharmaceutical drug or drug therapy to another;
(x) "price list" means a price list referred to in paragraphs 24 and 25 and includes a supplementary price list;
(y) "price to retailer" means the price of a drug at which it is sold to a retailer which includes duties and does not
include local taxes;
(z) "retail price" means the price fixed by the Government for a new drug under paragraph 5;
(za) "retailer" means a dealer carrying on the retail business of sale of drugs to customers;
(zb) "scheduled formulation" means any formulation, included in the First Schedule whether referred to by
generic versions or brand name;
(zc) "schedule" means a Schedule appended to this Order;
(zd) "wholesaler" means a dealer or his agent or a stockist engaged in the sale of drugs to a retailer, hospital,
dispensary, medical, educational or research institution or any other agency;
(ze) "wholesale price index" means annual wholesale price index of all commodities as announced' by the
Department of Industrial Policy and Promotion, Government of India, from time to time.
(2) All other words and expressions used herein and not defined but defined in the Act or the Drugs and Cosmetics Act,
1940 (23 of 1940) shall have the meanings respectively assigned to them in the said Acts.
.3. Directions to manufacturers of active pharmaceutical ingredients or bulk drugs or formulations.- The Government
may, -
(i) with a view to achieve adequate availability and to regulate the distribution of drugs, in case of emergency or
in circumstances of urgency or in case of non-commercial use in public interest, direct any manufacturer of any
active pharmaceutical ingredient or bulk drug or formulation to increase the production and to seli such active
pharmaceutical ingredient or bulk drug to such other manufacturer(s) of formulations and to direct formulators
to sell the formulations to institutions, hospitals or any agency as the case may be;
(ii) for the purpose of giving any direction under sub-paragraph (i), caii for such information from manufacturers
of active pharn>aceuticai ingredients or bulk drugs or formulations, as it may consider necessary and such
manufacturer shall furnish the required information within such time the Government may fix.
4. Calculation of celling price of a scheduled formulation.- (1) The ceiling price of a scheduled formulation of specified
strengths and dosages as specified under the first schedule shall be calculated as under: .
Step 1. First the Average Price to Retailer of the scheduled formulation i.e. P(s) shall be calculated as below:
Average Price to Retailer, P(s) = (Sum of prices to retailer of all the brands and generic versions of the
medicine' having market share more than or equal to one percent of the total market turnover on the
basis of moving annual turnover of that medicine) / (Total number of such brands and generic
versions of the medicine having market share more than or equal to one percent of total market
turnover on the basis of moving annual turnover for that medicine.)
Step 2. Thereafter, the ceiling price of the scheduled formulation i.e. P(c) shall be calculated as below:
P(c) = P(s).(l+M/100), where
38 THE GAZETTE OF INDIA : EXTRAORDINARY [Part II—Sec. 3(ii)]
P(s) .= Average Price to Retailer for the same strength and dosage of the medicine as
calculated in stepl above..
M = % Margin to retailer and its value =16
(2) The ceiling price calculated as per sub-paragraph (1) and notified by the Government shall be applicable
scheduled imported formulations also.
5. Calculation of retail price of a new drug for existing manufacturers of scheduled formulations.- (1) The retail price
of the new drug available in domestic market shall be calculated as provided in sub-paragraph (1) of paragraph 4.
(2) (i) the price to retailer of a new drug, not available in domestic market, shall be fixed by the Government on the
principles of "Pharmacoeconomics" of the new drug, on the recommendation of a Standing Committee of Experts
formed under paragraph 15.
(ii) the retail price of such new drug shall be fixed by adding sixteen percent margin to retailer on the price to
retailer as fixed in item (i):
6. Ceiling price of a scheduled formulation in case of no reduction in price due to absence of competition.- (1) where
the average price to retailer of a scheduled formulation, arrived at as per the formula specified in sub-paragraph (1) of
paragraph 4, has the effect of,-
(a) no reduction in average price to retailer with respect to the prices to retailer of the schedule formulation-
and '
to
(b) there are less than five manufacturers for that formulation having one percent or more
the ceiling price shall be calculated as under:-
market share.
(i) in the event of other strengths or dosage forms of the same scheduled formulation is available in the
list of scheduled formulation, the average price to retailer shall be calculated as under:
Stepl: First the Average Price to Retailer of-,such scheduled formulation i.e. P(s) shall be calculated as
under:
P{s) = P^,{l-(Pil■^Pi2■^...)/(N•100)} Where,
Pm = Price to Retailer of highest priced scheduled formulation under consideration.
P, = % reduction in Average Price to Retailer of other strengths and dosage forms (calculated
-- in stepl of sub-paragraph (1) of paragraph 4) in the list of schedule formulations w.r.t. the
highest priced formulation taken for calculating the average price to retailer of such
strengths and dosage forms.
as
N - Number of such other strengths or dosage forms or both
formulations
Step 2. Thereafter, the ceiling price of the scheduled formulation i.e. P(c) shall be calculated as under:
P(c) = P(s).(l+M/100), where
P|s) = Average Price to Retailer of the scheduled formulation
. hereinabove and
M = % Margin to retailer and its value=16
scheduled formulation is not available in the
^rhpH H f ^'^heduled formulations in same sub-therapeutic category as that of thescheduled formulation, then the Ceiling Price shall be calculated as under:
Stepl: First the Average Price to Retailer of such scheduled formulation
under:
in the list of schedule
as calculated in step 1
i.e. P(s) shall be calculated as
P{s) = Pm{l-{Pii-^Pi2-f...)/(N*100)}, Where,
Pm - Price of highest priced formulation taken for calculating the
the formulation under consideration..
P, = % reduction in Average Price to Retailer of other schedule formulations (calculated as in
sched.^P^f '"'Tr sub-therapeutic category as that of thescheduled formulation under consideration
calculating the average price to retailer.
N = Number of such other schedule formulations in
the scheduled formulation under consideration.
average price to retailer of
w.r.t the highest priced formulation taken for
same sub-therapeutic category as that of
I
1
[HPi II--g?5 3(ii)] ^ : 3THVrR
39
step 2. Thereafter, the ceiling price of the scheduled formulation i.e. P(c) shall be calculated as under;
P{c) = P(s)*(l+M/100), where
P(s) = Average Price to Retailer of the scheduled formulation as calculated in stepl above
and
M = % Margin to retailer and its value=16
Explanation.- where the scheduled formulation under consideration is coming under more than one sub-
therapeutic category, the Average Price to Retailer of the scheduled formulation shall be calculated after
taking into consideration the percentage reduction in Average Price to Retailer of other schedule
formulations under all such sub-therapeutic categories and the lowest average price to retailer shall be
taken for calculating the ceiling price of the scheduled formulation under consideration;
(iii) in case the other strengths or dosage forms of the scheduled formulation are not available in the
schedule and there is no sub therapeutic category of the scheduled under consideration, the ceiling price
shall be calculated as under;
Stepl: First the Average Price to Retailer of such scheduled formulation i.e. P(s) shall be calculated as
under;
P{s) = Pr,{l-{P|i+Pi2+...)/(N*100)} Where,
Pn, = Price of highest priced formulation taken for calculating the average price to retailer of
the formulation under consideration.
Pi = % reduction in Average Price to Retailer of other schedule formulations (calculated as in
stepl sub-paragraph (1) of paragraph 4) in same therapeutic category as that of the
scheduled formulation under consideration w.r.t the highest priced formulation taken for
calculating the average price to retailer.
N = Number of such other schedule formulations in same therapeutic category as that of the
scheduled formulation under consideration.
.Step2. Thereafter, the ceiling price of the scheduled formulation i.e. P(c) shall be calculated as under;
P(c) = P(s).|l+M/100), where
P{s) = Average Price to Retailer of the scheduled formulation as calculated in stepl above and
M = % Margin to retailer and its■value=16
Explanation.- where the scheduled formulation under consideration is coming under more than one
therapeutic category, the Average Price to Retailer of the scheduled formulation shall be calculated after
taking into consideration the percentage reduction in Average Price to Retailer of other, schedule
formulations under all such therapeutic categories and the lowest average price to retailer shall be taken
for calculating the ceiling price of the scheduled formulation under consideration.
(2) Notwithstanding anything contained in this paragraph, where the price has been fixed and notified by the
Government under the Drugs (Prices Control) Order, 1995 the provisions of sub-paragraph (1) shall not apply.
7. Margin to retailer.- While fixing a ceiling price of scheduled formulations and retail prices of new drugs, sixteen
percent of price to retailer as a margin to retailer shall be allowed.
8. Maximum retail price.- (1) The maximum retail price of scheduled formulations shall be fixed by the manufacture/s
on the basis of ceiling price notified by the Government plus local taxes wherever applicable, as under;
Maximum Retail Price = Ceiling price + Local Taxes as applicable
(2) The maximum retail price of a new drug shall be fixed by the manufacturers on the basis of retail price determined
by the Government plus local taxes wherever applicable, as under;
Maximum Retail Price = Retail Price + Local Taxes as applicable
9. Reference data and source of market based data.- (1) Initially, the source of market based data shall be the data
available with the pharmaceuticals market data specializing company - IMS Health (IMS) and if the Government deems
necessary, it may validate such data by appropriate survey or evaluation.
(2) The Government may in the due course of time come out with other appropriate mechanism of collecting or
obtaining the market based data related to drugs and the decision of Government with respect to collection or
obtaining of data shall be final.
(3) The market based data, for fixing the ceiling price of scheduled formulations for the first time after the notification
of this order, shall be the data of May, 2012.
40 THE GAZETTE OF INDIA : EXTRAQRniNARV
■ [Part II—SEC. 3(ii)]
a revision in the first schedule
six month of notification of revision in the first
under the provisions of the said order, up to 3l“ May 2012 shaii rema
Order, 1995, fixed and notified under the provisions of DrSgs (Pricrs t 'i q ̂
remain effective for one year from the date of notification of sulh nr 31 May, 2012, shaii
immediately thereafter the manufacturers may-revise the prices as LTfh' ’’"'if'
previous calendar year announced by Department of Industrial Promnti^ the annual wholesale price index for the
in the First Schedule of this order, fixed'a^d notS unShe p^Sns of the s^ald^
remain effective for further one year i.e. up to the 30‘^Mav'20l rf ' 2012, shall
as i„ casp erf „,h„
ran,™ effea.va for one ,aar from ,he data of notification of sTo te
quantity in the pack as the case may be. multiplying the same with the number
sita for that catego^TmldWn*“fspirflei m“lho 0™“'”jld ‘'''"'“I'' 'I'd ld«»«t
thareoddar,-shall ba taken as onit dosage “r calcltm.?^ T "■ “““ »' “«> “1 «>.
manufacturer- (1) A ™w”turt" fnXgTSJteT^^^ °! fannehad by a -
ceiling price (plus local taxes as applicable so fixed^^ formulations at a price higher than the. formula.,ons doumward no. axca.ding the calling price (plus l«.| tLa/a^rppfabTa)-
maximum retail
or
pack
rules
case may be, for thatper unit price of even non-scheduled medicines
ensure within a period of forty-five davs of thprice of such scheduled formulation does not exceed the c^lL I r f f notification that the
(2) All the existing manufactures of scheduled formuiaf ii- ' ^ local taxes as applicable),
scheduled formulations at a price lower than the ceiling price'fplL'kfca^f of
Government shall maintain their existing maximum retail priL notified by the
::lSS' '-^;~~™-csr,ledo„.paragraphs (2)''and JsTof'pVayaVh 16."
'IRtl mi ; SWIVTOT
41
thT»?™ltn'of" T °' f the prices shall be madethe provision of sub-paragraph (4) of paragraph 16.
14. Fixation of ceiling price of scheduled formulations.- (1) The Government shall fix and notify the ceiling prices of
man f r T f T' 'u provisions of the paragraphs 4 and 6, as the case may be and no
so fixedlTn'o^iherblt Go:etnm/:r'"'°" '''
as per
Spirable) fixL'"a^"d^no%-^7h\r'r''^''"‘^ formulation at a price higher than the ceiling price (plus local taxesppl.cable) fixed and notified by the Government, such manufacturers shall be liable to deposit the overcharged
amount along with interest thereon from the date of such overcharging. ®
15. Fixation of retail price of a new drug for existing manufacturers of scheduled formulations.- (1) The Government
2 rremind m rT- of this order with aView to recommend the retail prices of new drugs on the principles of "Pharmacoeconomics".
MidTd„'e'sMrh“""* *“6 ‘<“>8“ ""‘I as specified ip Nationai Ust of EssentialMedicines iaonches a new drug, such existing manufacturers shall apply for prior price approval of such new drug from
the Government in Form-I specified under Schedule-ll of this Order. ^
(3) On receipt of the application under sub-paragraph (2), in the event of the new drug available in domestic market
the Government shall fix the retail price of the new drug in accordance with the provision of sub-paragraph (1) of
to S d " r'" • not available in domestic market, the Government shall forward the sameto the Standing Committee of Experts who shall examine the application on the principles of "Pharmacoeconomics" and
Government within thirty days of the receipt of
(4) The Government shall on receipt of recommendation under sub-paragraph (3), within thirty days, fix the retail price
of such new drug and such price shall be applicable to such applicant of such new drug.
(5) Where existing manufacturer of scheduled formulation fails to apply for prior approval of the price of the new drug
in Form-k such manufacturer shall be liable to deposit the overcharged amount over and above such price fixed and
notified by the Government, if any, along with interest thereon from the date of launch of the new drug, in addition to
the penalty.
as
(6) No existing manufacturer of a scheduled formulation shall sell such
, . , a new drug at a price higher than the retail price(p us local taxes as applicable) fixed by the Government for such new drug and In case such a manufacturer is found to '
sell such a new drug at a price higher than the retail price (plus local taxes as applicable) fixed by the Government, such
manufacturer of the new drug shall be liable to deposit the overcharged amount along with interest from the date of
overcharge, in addition to the penalty.
i
16. Revision of ceiling price of scheduled formulations.- (l) The Government shall revise the ceiling prices of
scheduled formulations as per the annual wholesale price index (WPI) for preceding calendar year on or before April
of every year and notify the same on the l" day of April every year.
(2) The manufacturers may increase the maximum retail price (MRP) of scheduled formulations once in a year, in the
month of April, on the basis of the wholesale price index with respect to previous calendar year and no prior approval
of the Government in this regard shall be required.
(3) Information about the revision, if carried out, shall be forwarded to the Government iri either electronic or physical
form in Form-ll within a period of fifteen days of such revision and non-submission of information under this sub-
paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be
liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest
thereon from the date of overcharging.
(4) In case of decline in wholesale price index, there shall be a corresponding reduction in the maximum retail price and
in case of scheduled formulations produced or available in the market before the date of notification of revised ceiling
price, the manufacturers shall ensure within a period of forty-five days of the date of such notification that the
maximum retail price (MRP) of such scheduled formulation does not.exceed the revised ceilihg price (plus local taxes c;
applicable) and information about the revision shall be sent to the Government in either electronic or physical^orm in
Form-ll within a period of fifteen days of such revision.
as
(5) Non-submission of information under the sub-paragraph (4) shall be construed as non reduction in maximum retail
price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the
maximum retail price revised based on decline in wholesale price index, alongwith interest thereon as overcharged
amount from the date of overcharging.
/9?g4G//3-6
42 THE GAZETTE OF INDIA : EXTRAORDINARY [Part II—Sec. 3(ii)] ̂
SMatenffh"'? '' ‘he first schedule, clearly stating the
Health and FTrl'ilflharea^^^ Sovernment within slsty days of receipt of communication from the Ministry ofHealth and Family Welfare and the amendment(s) or revision, if required, in the first schedule shall hp nm-ifipH Inri
thereafter the celling price|s| for the medici„e(s| added In the first schedule shall be lx as p , he ro.l on of hi
order Within a period Of Sixty days from the date Of the notification. per tne provisions of this
(2) The medicines omitted from the first schedule shall fall under the categoty of non-scheduled formulations
18. Rev,s,on of celling price on the basis of moying annual turnover (MATI.- The revision of celling prices
of moving annual turnover value shall be carried out,-
five years from the'date of^fi'xin'g “hiSrprl^el'^this 0^0^ ̂hictv'lMfeXlf
prices (MRP) P«‘l'rd‘r“esJnTdlt tte non'^redS"^^^^ "'“™™ ‘"“I
wrTreS:'%at“rof.maximum retail price for next twelve ntont™ " ' ‘he same to the level of ten percent
on the basis
or
or the
i~p“SL“:;dti:^:;:'rar^^^ .^e date of
availability of scheduled .formu°Lio!lf allf thrSr'phal-maIlltfcTi""'T P^oduc'tion and
formulation and the manufacturer of scheduled formulations and thP f contained in the . scheduled
.hescheduledformulationshallfurnlshthelnforJrnlraLrn;!^^^^^^
Shall issue a nlli°clllTalsl1nt™eSr^^^^^^^ ^be market
SIX month prior to the intended date of discontinuation and tho r " °*^^bis order in this regard at least
rrianufacturer of the scheduled formulatl Z^^^^^^^^^ ^i-t the
iSatr within a p^eriod^S;
j orugsrequire a manufacturer, importer or distributor as the case may bmoost' Government may by notice, .
provisions of the Drugs (Prices Control) Order 1979 on or bLr'p^h ^ under thePrices Equalisation Account and the rnalufactuVer im^lrter ^be Drugs
.hnoup, i„,„ ,hu suid account within such time us th. Govornmunt muy specify in the Il'd™ to ““
Order, end the umount deposited uIldtoShwgmp^HrsSlbe^^^^^^ f" of this
price and the common selling prfce “o^^L^tht wsl^mly^L^^t^^^ T? bis retention
poductlon, or seeurtng the equltehle distribution end avellebilty at
..)meed„gtheexpensesincurredbytheGovemmentindlsch,.ingthefunc;ionsund:rthisperugru^,.end
;
[tiFi II-Tgw^3(ii)] 43
(c) promoting higher education and research in Pharmaceutical Sciences and Technology and for the purposes
incidental thereto.
23. Recovery of overcharged amount under Drugs Prices Control Orders 1987 and 1995.- Notwithstanding anything
contained in this order, the Government shall by notice, require the manufacturers, importer.-or distributor or as the
case may be, to deposit the amount accrued due to charging of prices higher than those fixed or notified by the
Government under the provisions of Drugs (Prices Control) Order, 1987 and Drugs (Prices Control) Order, 1995 under
the provisions of this Order.
24. Carrying into effect the price fixed or revised by the Government, its display and proof thereof.- (1) For all the
scheduled formulations having maximum retail price (MRP) higher than ceiling price (plus local taxes as applicable), the
manufactures shall revise the maximum retail price (MRP) not exceeding the ceiling price (plus local taxes as
applicable):
Provided that in case of scheduled formulations produced or available in the market before the date of notification of
ceiling price, the manufacturers shall ensure within a period of forty-five days of the date of the notification that the
maximum retail price of such scheduled formulation does not exceed the ceiling price (plus local taxes as applicable).
(2) Every manufacturer of a schedule formulation intended for sale shall display in indelible print mark, on the label of
container of the formulation and the minimum pack thereof offered for retail sale, the maximum retail price of that
formulation based on the ceiling price notified in the Official Gazette or ordered by the Government in this behalf with
the words "Maximum Retail Price" preceding it and the words 'inclusive of all taxes' succeeding it.
(3) Every manufacturer shall issue a price list and supplementary price list, if required, in Form V to the dealers. State
Drugs Controllers and the Government indicating reference to such price fixation or revision as covered by the order or
Gazette notification issued by the Government, from time to time.
(4) Every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the
manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily
accessible to any person wishing to consult the same. -
25. Display of prices of non-scheduled formulations and price list thereof.- (1) Every manufacturer of a non-Scheduled
formulation intended for sale shall display in indelible print mark, on the label of container of the formulation and the
minimum pack thereof offered for retail sale, the maximum retail price of that formulation with the words "Maximum
Retail Price" preceding it and the words 'inclusive of ail taxes' succeeding it.
(2) Every manufacturer shall issue a price list and supplementary price list, if required, of the non-Scheduled
formulations in Form-V to the dealers. State Drugs Controllers and the Government indicating changes, from time to
time.
#
(3) Every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the
manufacturer or importer, on a conspicuous part of the premises where he carries on business in a manner so as to be
easily accessible to any person wishing to consult the same.
26. Control .of sale prices of formulations.- No person shall sell any formulation to any consumer at a price exceeding
the price specified in the current price list or price indicated on the label of the container or pack thereof, whichever is
less.
27. Sale of split quantities of formulations.- No dealer shall sell loose quantity of any formulation at a price which
exceeds the pro-rata price of the formulation.
28. Manufacturer, distributor or deaier not to refuse sale of drug.- Subject to the provisions of the Drug and
Cosmetics Act, 1940 (23 of 1940) and the.rules made thereunder, -
(a) no manufacturer or distributor shall withhold from sale or refuse to sell to a dealer any drug without good and
sufficient reasons;
(b) no dealer shall withhold from sale or refuse to sell any drug available with him to a customer intending to
purchase such drug.
29. Maintenance of records and production thereof for inspection.- Every manufacturer shall maintain records
relating to the sales of individual active pharmaceutical ingredients or bulk drugs manufactured or imported and
marketed by him, as the case may be, and the sales of formulations units and packs and also such other records as may
be directed from time to time by the Government and the Government shall have the power to call for any record and
to inspect such records at the premises of the manufacturer.
30. Power of entry, search and seizure.- (1) Any Gazetted Officer of the Central Government or of ̂'State Government,
as the case may be, authorised by a general or special order by the Central Government or by th^ State Government, as
44 . THE GAZETTE OF INDIA : EXTRAORDINARY [Part II—Sec. 3(ii)]
the case may be, in this behalf may, with a view to securing compliance with this Order or to satisfy himself that the
provision of this Order have been complied with-
(a) enter and search any place;
(b) seize any drug, alongwith the containers, packages or coverings in which the drug is found, in respect of which
he suspects that any provision of this Order has been, is being, or is about to be contravened, and thereafter take
ail measures necessary Tor securing production of the drug, containers, packages or coverings, so seized, in a court
of iaw and for their safe custody pending such production;
(c) seize any document, such as, cash memo or credit memo books, books of account and records of purchase and
saie of the drugs in respect of which he suspects that any provision of this Order has been, is being, or is about to
be contravened.
(2) The provisions of Code of Criminal Procedure, 1973 (2 of 1974), relating to search and seizure shall, so far as may be,
apply to searches and seizures under this Order.
31. Power to review.- Any person aggrieved by any notification issued or order made under paragraphs 4, 5 and 6 of
this Order, may appiy to the Government for a review of the notification or order within a period of thirty days of the
date of publication of the notification in the Officiai Gazette or the receipt of the order by him, as the case triay be, and
the Government may make such order on the application as it may deem proper: .
Provided that pending a decision by the Government on the appiication submitted under the above paragraph, no
manufacturer shali seil a scheduied formulation or a new drug, as the case may be, at a price exceeding the ceiling price
or retail price, as the case may be, fixed by the Government of which a review has been applied for.
32. Non-application of the provisions of this order in certain cases.- The provisions of this order shall not apply to, -
(i) a manufacturer producing a new drug patented under the indian Patent Act, 1970 (39 of 1970) (product patent)
and not produced elsewhere, if developed through indigenous Research and Deveiopment, for a period of five
years from the date of commencement of its commercial production in the country,
(ii) a manufacturer producing a new drug in the country by a new process deveioped through indigenous Research
and Deveiopment and patented under the indian Patent Act, 1970 (39 of 1970) (process patent) for a period of five
years from the date of the commencement of its commercial production in the country,
(iii) a manufacturer producing a new drug involving a new delivery system developed through Indigenous Research
and Deveiopment for a period of five years from the date of its market approval in india:
Provided that the provision of this paragraph shali apply only when a document showing approval of such
drugs from Drugs Controller General (India) is produced before the Government.
Explanation.- Notwithstanding anything contained in this Order, for the purpose of this paragraph "new drug" shall
have the same meaning as is assigned to under rule 122E of the Drugs and Cosmetics Rules, 1945.
new
[File No. 31011/17/2012-PI-ll]
SHAMBHU KALLOLIKAR,Jt. Secy.
SCHEDULE-1 .
(See Paragraphs-2(t),2(zb))
P. S and T appearing in NLEM 2011 denote essentiality at Primary, Secondary and Tertiary levels respectively.
NATIONAL LIST OF ESSENTIAL MEDICINES 201 1
Section: 1 - Anesthesia
1.1 General Anesthetics and Oxygen
Medicines Category Route of Administration Strengths
Ether S,T Inhalation
Halothane with vaporizer S,T Inhalation
45
ie\
InhalationS,TIsoflurane
#
10 mg/ml,
50 mg / ml
InjectionP, S,TKetamine Hydrochloride
InhalationP, S,TNitrous Oxide
t
InhalationP, S,TOxygen
0.5 g, 1 g powderInjectionS,TThiopentone Sodium
Added Medicines
InhalationTSevoflurane
1 % oil suspensionInjection
. 1.2 Local Anesthetics
P,S,TPropofol
Route of Administration/
Dosage Form
StrengthsCategoryMedicines
. 0.25%, 0.5%, 0.5%
to be mixed with
7.5% glucose solution
Bupivacaine
Hydrochloride
InjectionS,T
2-5%, .
1-2%,
5% +7.5% Glucose-
Topical Forms,
Injection,
Spinal
P, S,TLIgnocaine Hydrochloride
1%, 2% +
Adrenaline1:200,000
Lignocaine Hydrochloride
+ Adrenaline
InjectionP, S,T
Added Medicines
CreamTEM LA cream
1.3 Preoperative Medication and Sedation for Short Term Procedures
Route of Administration/
Dosage Form
StrengthsCategoryMedicines
0.6 mg / mlInjectionP, S, TAtropine Sulphate
5 mgTablets
Injection,
Syrup,
Suppository
5 mg / ml
2mg/5ml
P,S,T
Diazepam S,T
5ma
1 mg / ml
5 mg / mlInjectionP, S,TMidazolam
10 mg / mlInjectionS,TMorphine Sulphate
Promethazine
5 mg / 5 mlSyrupP, S, T
Section: 2 - Analgesics , Antipyretics, Nonsteroidal Anti-inflammatory Medicines, Medicines used
Gout and Disease Modifying Agents used in Rheumatoid Disordersto treat
7 1-Nnn.nnioid Analgesics, Antipyretics and Nonsteroidal Anti-inflammatory IVledicines
Route of Administration/
Dosage Form _
Tablets
Strengths
CategoryMedicines
325, 350 mg
PAcetyl Salicylic , S, T
\
46 THE GAZETTE OF INDIAr EXTRAORDINARY [Part ll—Sec. 3(ii)]
Acid
T Tablets 50 mg
25 mg / ml
200 mg, 400 mg
100mg/5ml
Diclofenac
T Injection
Tablets
Syrup
Ibuprofen P, S, T
P, S,T Injection 150 mg/ml
P, S,T Syrup
Tablets
125 mg/5ml
500 mg
Paracetamol
P, S,T
P, S,T Suppository
2,2 Opioid Analgesics
80 mg, 170 mg
Route of Administration/.
Dosage Form
Medicines Category %Strengths
Injection 10 mg/ml ■
Morphine Sulphate S,T
Tablets 10 mg
Added medicines
Injection
Cap
Injection
Tramadol 50 mg/ml
50 mg,100 mg
50ug/ml 2ml ampoule
S,T
Fentanyl
S,T
2.3 Medicines used to treat Gout
TabletsAllopurinol S, T
100 mg
0.5 mg
Colchicine S,T Tablets
2.4 Disease modifying agents used in Rheumatoid disorders
SAzathioprine ,T Tablets 50 mg
Methotrexate S,T Tablets 5mg, 7.5mg. lOmq
Sulfasalazine S,T Tablets 500 mg
Added medicines
Hydroxychloroquine
phosphate
Leflunomide
S,T Tablets 200 mg
S,T Tablets lOmg, 20 mg tab
Section: 3 - Antiailergics and Medicines used in Anaphylaxis
Route of Administration/
Dosage Form
Injection
Medicines Category
Strengths
Adrenaline Bitartrate
Chlorpheniramine Maleate
Dexchlorpheniramine
Maleate
Dexamethasone
P, S, T
1 mg / ml
P, S,T Tablets
Syrup
4 mg
P, S, T 0.5 mg/5 ml
P, S,T Tablets 0.5 mg
Injection 4 mg/mlHydrocortisone Sodium
Succinate
Pheniramine Maleate~~
Prednisolone
P, S,T Injection 100 mg
P, S, T
P, S, T
Injection
Tablets
22.75 mg / ml
5 mg, 10 mg, 20
mqPromethazine P, S,T Tablets 10 mg, 25 mg
5 mg / 5 mlSyrup
Added Medicines
Cetrizine P,S,T Tablets
Syrup
lOmg
5 mg/ml
Section: 4 - Antidotes and Other Substances used in Poisonings
4
4.1: Nonspecific
Route of Administration/
Dosage Form
Oral
Medicines
Activated Charcoal
Category
Strengths
P,S,T
4.2: Specific
Medicines I Category Route of Administration/
Strengths
47[«mi 11-^005 3(ii)] ^Tti : 3rei<'3R?I
Dosage Form
1 mg/mlInjection
Injection Polyvalent
Solution/ Lyophilyzed
Polyvalent Serum
P,S,TAtropine Sulphate
Specific Antisnake venom P,S,T
4
100 mg/mlInjection
Injection
P.S.TCalcium gluconate
500 mgS,TDesferrioxamine
mesylate
10 nig / mlInjection■ t S,TMethylthioninium chloride
(Methylene blue)
Penicillamine 250 mgTablets or CapsulesS,T
50 mg / ml
0.1 mg / ml
Injection in oilS,TDimercaprol
InjectionTFlumazenil
30 mg / mlInjection
Injection
S,TSodium Nitrite
250 mg/ ml
0.4mg/ml
25 mg/mt
S,TSodium Thiosulphate
InjectionP,S,TNaloxone
InjectionP,S,TPralidoxime Chloride(2-
PAM]
Added medicines:
200 mg/ml(5 ml) ,P.S.T 1 InjectionN-acetylcysteine
Section: 5 - Anticonvulsants/ Antiepileptics
Route of Administration/
Dosage Form
StrengthsCategoryMedicines
lOOmg
200mg
100 mg/5mr
5 mg /ml
Tablets. P, S,TCarbamazepine
Syrup
InjectionP,S,TDiazepam
500 mg /mlInjectionS,TMagnesium sulphate
30 mg, 60 mg
200 mg/ml
20 mg/5ml
TabletsP,S,TPhenobarbitone
Injection
Syrup
ST
P.S.T
P.S.T 50 mg,
lOOmg
25mg/ml
50 mg/ml
Capsules or Tablets
Syrup
Injection
Phenytoin Sodium
200 mg,
500mg
200 mg/5ml
Tablets
Syrup
P.S.TSodium Valproate
100 mg/mlInjectionT
Added Medicines
2m9/mlInjectionTLorazepam
Section: 6 - Anti-infective Mcilicincs
6.1 Anthelminthics
6.1.1 Intestinal Anthelminthics
Route of Administration/
Dosage Form
StrengthsCategoryMedicines
400 mg
200 mg/ 5 ml
Tablets
Suspension
P.S.TAlbendazole
Added Medicines
4.5 gm
750mg/5ml
Tablets
Solution
P.S.TPiperazine
6.1.2 Antifilarials
Route of Administration/
Dosage Form
Strengths
CategoryMedicines
50 mgTabletsDiethvicarbamazine citrate P.S.T ^ ^
^ 613 Antlschlstosomals and Antitrematode Medicines
Route of Administration/ |CategoryMedicines
Strengths
t
48 THE GAZETTE OF INDIA : EXTRAORDINAR v
[Part 11—Sec. 3(ii)i
Dosage Form
Tablets
Praziquantel S, T
600 mg
6.2 Antibacterials
_6.2.1 Beta lactam medicineg
Route of Administration/
Dosage Form
Powder for suspension
Capsules •
Capsules
Powder for suspension
Injection
Category
S,T
P
Medicines »
Strengths
125 mg / 5 ml
250 mg. 500 mo
250 mg, 500 mg
125 mg / 5 ml
500 mg
Amoxicillin
Ampicillin ,S,T
Benzathine'
Benzylpenicillin
Cefotaxime
P.S.T ' Injection 6 lacs, 12 lacs
units
125 mg, 250 mg
500 mp
250mg. 1g
250 mg. 1 g
125 mg/5 ml
250 mg. 500 mg
250 mg, 500 mg
250 mg
125mq/ 5 ml
S, T ■ Injection
Ceftazidime
Ceftriaxone
Cephalexin
S, T Injection
Injection
Syrup
Capsules
Capsules
Injection
Liquid
S, T
P,S,T
Cloxacillin P,S,T
Added Medicines
Amoxicillin+Clavulinic acid T Tablets
Powder for suspension
Injection
Tablet
6.2.2 Other antibacteriak
Route of Administration/
Dosage Form
Injection
Tablets
Suspension
Injection
Injection
Tablets
Tablets
T
S,T
S,T
P,S,T
P,S,T
625 mg
228.5mg/5ml
600mg. 1.2om
100. 200mo
Cefixime
Medicines Category
StrengthsAmikacin
250 mg/2 ml
100, 250,500mg
100mg/5ml
500mq
200 mg /100 ml
■ 250 mg, 500 mn
80 + 400 mg
160+800 mg
40 + 200 mg / 5
Azithromycin
Ciprofloxacin
Hydrochloride
C6-Trimoxazole
(Trimethoprim +
Sulphamethoxazole)
Suspension
Doxycyciine
Erythromycin
Estolate
mlP,S,T
Tablets
Syrup
Tablets
Injection
100 mg
125 mg/5 ml
250 mg, 500 mg
10 mg/ml, 40
mg/ml
200mg,400m
g
500mg/100ml
_ 100mg/5ml
100 mg
500 mg
500 mg, 1 q
P,S,T
Gentamicin P,S,T
Metronidazole P,S,T
Tablet
Injection
Syrup
Tablets
Tablets
Nitrofurantoin
Sulphadiazine
Vancomycin
Hydrochloride
P,S,T
S, T
T
Injection
rosy medicinna
Route of Administration/
Dosage Form
Capsules
6.2.3 Antilei
CategoryMedicines
Strengths
50 mg. 100 mg
50 mg, 100mq
--'Q rng. 300 me15
Ciofazimine
Dapsone
Rifampicin
P^T
Tabfets
bT^’LL.J——Caps^jteT^Frghj^P-Z.4 Antituberculosia mnriirin,.
Category
~ P.S.T
Route of AdministrationMedicines
EthambutoT
/
Dosage Form
Tabiets
Strengths
200 mg. 40q7[^
49wra ̂ TOT5 : areii-wil[tun II--!3ir5 3(ii)]
#-■ 600 mg, 800 mg
50 mg, 100 mg,
300 mg
100 mg/5ml
Tablets
Syrup
Tablets
Syrup
P,S,TIsoniazid
100 mg, 200 mg
50 mg / 5 ml
500 mg, 750 mg,
1000 mg, 1500
* S,T.Ofloxacin
Tablets mgP,S,TPyrazinamide
50 mg, 150 mg,
300 mg,450 mg
100 mg/5 ml
Capsules/Tablets-
SyrupP,S,TRifampicin
. Streptomycin
Sulphate 0-75 g, 1 gInjection- ~P:SJ
6.3 Antifungal medicines
. Route of Administration/
Dosage FormCategory StrengthsMedicines
50 mgInjection
Pessaries
S,TAmphotericin B
100 mg, 200 mg.
2%GelP,S,TClotrimazole
50 mg, 100 mg,
150 mg,
200 mg
125 mg, 250 mg
Fluconazole
Capsules or TabletsS,T
Capsules or TabletsP,S,TGriseofulyin
500,000 lU
100,000 lU
Tablets
PessariesP,S,T ,Nystatin
6.4 Antiviral medicines
6.4.1 Antiherpes medicines
Route of Administration/
Dosage Form
Tablets'
Category StrengthsMedicines
200 mg, 400 mg
250 mg, 500 mg
400 mg / 5 ml
S,TAcyclovir Injection
Suspension
6.4.2 Antiretroviral medicines
6.4.2.1. Nucleoside reverse transcriptase inhibitors
Route of Administration/
Dosage FormCategory Strengths
Medicines
250 mg, 400 mg
150 mg
150 mg+ 200
mg+ 30 mg
■■ 150 mg + 300
TabletsS,TDidanosine
TabletsS,TLamivudine
Lamivudine + Nevirapine +
y'" Stavudine TabletsS,T
Lamivudine + Zidovudine
maTabletsS,T
15 mg, 30
mg, 40 mg
100 mg, 300
CapsulesS,TStavudine
mgTabletsS,TZidovudine
ADDED MEDICINES
30mg+ 150mgTabletsS,TStavudine+
Lamivudine ■ 300mg+
150mg+
200mg
TabletsZidovudine+
Lamivudine+
Nevirapine
4
6.4.2.2 Mnn.niicleoside reverse transcriptase inhibitor i
Route of Administration/
Dosage Form
StrengthsCategoryMedicines
200 mg,
600 mgCapsules■ S,TEfavirenz . 200 mg
50 mg / 5 ml
Capsules
SuspensionS.TNevirapine
6.4:2.3 Protease inhibitors
Route of Administration/
Dosage Form
Capsules
Category
S
Strengths
200 mg,
Medicines
,TIndinavir
50 THE GAZETTE OF INDIA : EXTRAORDINARY
[Part II—Sec. 3(ii)1
Nelfinavir S.T Capsules 250 mg
100 mg,Capsules
Syrup ■
Ritonavir S,T
400 mg / 5miSaquinavir S,T Capsules
6.5 Antiprotozoal Medicinea
6j.1 Antlamoebic and Antigiardlasls medlr.lnna
Route of Administration/
Dosage Form
Category
200 mg
'¥■
Medicines
Strengths
Diloxanide Furoate P.S.T Tablets 500 mg
200 mg, 400 mg
500 mg /IQQ ml
Metronidazole P,S,T Tablets
Injection
6.5.2 Antileishmaniasis medicines
Route of Administration/
Dosage Form
CategoryMedicines
Strengths
Amphotericin B S,T injection
Injection
50 mgPentamidine isothionate
Sodium Stibogluconate
S,T
200 mg
100 mg/ml
S,T Injection
6.5.3 Antimalarial Medicinea
6.5.3.1 For curative treatment
Route of Administration/
Dosage Form
CategoryMedicines
Aftesunate (To be used
only in combination with
Sulfadoxine
+Pyrimethamine)
Strengths
P,S,T Tablets 50 mg
Tablets
Injection
Syrup
Chloroquine phosphate 150 mg base
40 mg / ml
50 mg / 5 ml
2.5 mg. 7,5 mg
25 mg
300 mg
300 mg / ml
P,S,T
Primaquine
Pyrimethamine
Quinine sulphate
Sulfadoxine +
Pyrimethamine
P,S,T Tablets
TabletsP,S,T
P,S,T Tablets
InjectionST
P,S,T Tablets 500 mg + 25 mg
Medicines addedClindamycin
Tablet 150, 300mg6.5.3.2 For prophylaxis
Category Route of AdmMedicines inistration/
Dosage Form Strengths
Medicines added
Mefloquine S,T Tablet T 250 mg base
^ Antipli^mocystosl^m[JArnito^i;j^^
___JW^dicines Category
Co-Trimoxazole p s j
(Trimethoprim +
Sulphamethoxazole)
Pentamidine Isothionate
Route of Administrat
Suspension
S I
medicinesion/
Dosage Form
Tablets
Strengths
80 + 400 mg.
160+800 mg
40 + 200 mg/5
.'i.
ml,T njection 200 mg
Section: 7-Antimigraine medicines
7.1: For treatment of aciitn attack
Category Route of AdministraMedicines
Acetyl Salicylic Acid
Dihydroerqotamins
Paracetamol
tion/
Dosage Form
L Tablets
Strengths
P,S,T
300 - 350 moS, T Tablets
-—J Tablets
7.2: For Prophylaxis
Route of Administration/
Dosage Form
-Tablets
1 mgP,S,T
500 mg
Medicines
Propranolol
hydrochloride
Category
Strengths
^Omg, 40 mgP,S,T.
,[»nnll-w3(ii)] 51
Section: 8 - Antineoplastic, immunosuppressives and medicines used in palliative care
8.1: Immunosuppressive medicines
Route of Administration/
StrengthsMedicines Category
Dosage Form
Tablets 50 mgAzathioprine
Cyclosporine
T
10 mg, 25 mg,
50 mg, 100 mg
T Capsulest
Concentrate for Injection 100 mg/ml
8.2: Cytotoxic medicines
Route of Administration/
StrengthsMedicines Category
Dosage Form
0.5 mgInjectionActinomycin D
Alpha Interferon
Bleomycin
Busulphan
Cisplatin
T
3 million lUInjectionT
15 mgInjectionT
Tablets 2 mgT
10 mg/vial
50 mg / vial
InjectionT
50 mg, 200 mg
500 mg
Tablets
InjectionTCyclophosphamide
100 mg/vial
500 mg/vial
1000 mg/vial
Cytosine
arabinoside
InjectionT
Capsules '
Injection
50 mg, 100 mgTDanazol
10 mg, 50 mg•T. Doxorubicin
100 mg
100 mg/ 5 ml vial
Capsules
InjectionTEtoposide
250 mg
250 mg / 5 ml
TabletTFlutamide
InjectionT5-Fluorouracil
3 mg/ml
200 mg
InjectionTFolinic Acid "
Gemcita.bine
hydrochloride
L- Asparaginase
InjectionT . Igm
5000 KU.InjectionT
2 mg, 5 mgTabletTMelphalari
50 mg
100 mg/ml
Tablet
InjectionTMercaptopurine
2.5 mg
50 mg / ml
Tablet
InjectionTMethotrexate
10 mgInjection
Injection
Mitomycin-C
30 mg / 5 ml
50 mg
V Paclitaxel
CapsulesTProcarbazine
Vinblastine 10 mgInjectionT
sulphate
1 mg / mlInjectionT-Vincristine*
Added medicines
150 mg, 450 mgInjectionTCarboplatin
vial
500 mg
20 mg vial
1 gm/2ml vial
Injection
Injection
Injection
TDacarbazine
TDaunorubicin
TIfosfamide
200 mgInjection
Injection
Tablets
TMesna
50 mg vial
TOxaliplatin
100 mg, 400 mg
TImatinib
52 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)1
(P- Chlorambucil | T Tablats 2 mg
8.3; Hormones and antihormonaa
Route of Administration/
Dosage Form
Medicines Category . Strengths
Tablets 5 mg
V
Prednisolone S,T 20 mg, 25 mg (as
sodium phosphate or
succinate)
60 mg
10 mg, 20 mg
Injection
Raloxifene Tablets
.Tamoxifen
Qtrate
T Tablets
8.4: Medicines used in palliative care
Route of Administration/
Dosage Form
CategoryMedicines Strengths
Morphine
Sulphate T Tablets 10 mg
Tablets 4 mg, 8 mg
Ondansetron S,T Injection 2 mg/ml
Syrup 2 mg/5 ml
Added Medicines
Filgrastim Injection
Tablets
1 ml vial
■ 100 mg
■ Allopurinol T
Section: 9 -Antiparkinsonism medicines
Route of Administration/
Dosage Form
Medicines Category Strengths
Bromocriptine
Mesylate
S,T Tablets 1.25 mg, 2.5 mg
Levodopa+
Carbidopa
P,S,T Tablets 100 mg+10 mg
250 mg+25 mg
100 mg+25 mg
■2 mg
Trihexyphenidyl
Hydrochloride
P,S,T Tablets
Section: 10 -Medicines affecting the blood
10.1: Antianaemia medicines
Route of Administration/
Dosage Form
Medicines Category Strengths
Cyanocobalamin. P, S,T Injection 1 mg/ml. Ferrous
Sulphate/
Fumrate
P,S,T Tablets Tablets equivalent to
60 mg elemental iron
25mg elemental iron
(as sulphate)/ml
1 mg;5mg
50 mg iron/ml
10 mg
Oral solution
Folic Acid P,S,T ' Tablets
Iron Dextfan S,T Injection
Pyridoxine P,S,T Tablets
10.2: Medicines affecting coagulation
Route of Administration/
Dosage Form
Medicines Category Strengths
Heparin Sodium S, T 1000lU/ml
5000lU/ ml
Injection
Protamine
Sulphate S, T Injection 10 mg/rril
Phytomenadione
Warfarin sodium
P, S, T Injection 10 mg/mlS, T Tablets 5 mg
Added Medicines
Enoxaparin T Injection 40mg, 60ma
53i^Ra ̂ wra : 3TOI*OT[ilFI 3(ii)]
Section: 11 -Blood products and Plasma substitutes
11,1: Plasma Substitutes
Route of Administration/ StrengthsCategoryMedicines Dosage Form
Inlection 10%P,S,TDextran-40
6%InjectionP,S,TDextran-70
Fresh frozen
plasma
■ Hydroxyethyl
Starch
(Hetastarch)
Polygeline
InjectionT
(
6%InjectionS, T
3.5%Injection
H ■}-. Plasma fractions for specific use
Route of Administration/
Dosage Form
S,T
StrengthsCategoryMedicines
5%, 20 %Injection
Injection
S,TAlbumin
S, T ■Crvoprecipitate
Factor VIII
Concentrate
DriedInjectionS.T
Factor IX
Complex
(Coagulation
Factors II,VII, IX,
DriedInjectionS,T
Platelet Rich
Plasma
InjectionS,T
Section: 12 -Cardiovascular medicines
12.1: Antianoinal medicines
Route of Administration/
Dosage Form
StrengthsCategoryMedicines
75rTig, lOOmg,
350 mg
soluble/dispersible
30 mg, 60 mg
Acetyl salicylic
acid
TabletsP,S,T
TabletsS,TDiltiazem 0.5 mg
5mg/ml
Sublingual Tablets
Injection
P,S,T-Glyceryl Trinitrate
10 mg,
20 mg
Isosorbide 5
Mononitrate/
Dinitrate
TabletsP.S,T
25 rfig; 50 mg
^ 1 mg/ml
Tablets
InjectionP.S,TMetoprolol
Added Medicines
75 mgTabletsTClopidogrel
12.2: Antiarrhvthmlc medicines
Route of Administration/
Dosage Form
StrengthsCategoryMedicines
3 mg/mlInjectionS,TAdenosine 100 mg, 200 mg
50 mg/ml (3 ml
annpoule)
Tablets
Injection
S,TAmiodarone
Tablets 30 mg, 60 mgS,T
Diltiazem
a 5 mg/ mlT Injection
10 mg / ml
TEsmolol Injection
1%, 2%InjectionS,TLignocaine
Hydrochloride
Procainamide
250 mg
lOOmg/ml
Tablets
InjectionTHydrochloride
Verapamil I
40 mg, 80 mgTablets
54 THE GAZETTE OF INDIA : EXTRAORniNARv
[Part 11—Sec. 3(ii)i
L Injection
12.3: Antihypertensive medicines
Route of Administration/
Dosage Form
2.5mg/ml
Medicines Category
Strengths
Amiqdipine P,S,T 2.5 mg,
-5.^9:
Tablets
«
Atenolol P,S,T . 50 mgTablets
Enalapril
Maleate
Losartan
Potassium
Methyldopa
100 mo
2.5 mg, 5mg
1.25mq/ml
P,S,T
Tablets
Injection
Tablets
T
S.T
25 mg,
50 mgP,S,T Tablets
Capsules
Tablets
Sustained release tablets
or capsules
injection
250 mg
Nifedipine 5 mg, lOmg
10mg, 20mg
10mg, 20mg
S,T
Sodium
Nitroprusside
T
50 mg/ 5 ml
Added Medicines
Hydrochlorthiazide P,S,T 12.5,Tablets
25 mg
12.4: Medicines used in heart faihiTr
Route of Administration/
Dosage Form
^ Tablets
Injection
Elixir
S,T
Medicines Category
StrengthsDigoxin
0,25 mg
0.25 mg/ml
0.05 mq/mlDobutamine
Dopamine
Hydrochloride
S, T
Injection 50 mg / mlS.T
Injection
40 mg / ml
j2.S: Antithrombotic mnriirinps
Route of Administration/
Dosage Form
Medicines Category
Strengths
Acetyl salicylic 75mg,
lOOmg,
350 mg
soluble/dispersihip
P.S.Tacid Tablets
S,T InjectionHeparin Sodium
1000 lU/ml
5000 lU/ml
S, TStreptokinase Injection 750,000 lU
15,00,000
lUT
InjectionUrokinase . 500,000
lU/ml
10.00.000 lU/mlNew uategorv - ADnpn
12.6 Hypoiipidemir.
1 Tablets
Atorvastatin P.S.T
5 mg, 10 mg '
Section: 13 -Dirmatological medicines (Topical)
13.1: Aniitunqal medicinp«
Route of Administration/
Dosage Form
_—Ointment or Cream
13.2: Antiinfective medicines '
Route of Administration/
Dosage Form
Medicines Category
StrengthsMiconazole P.S.T
2%
Medicines
Acyclovir
Framycetin
Sulphate
Methyirosanilinium
Chloride (Gentian
Category
Strengths
S.T
Cream
5%
P.S.T
Cream
0.5%
P.S.T Aqueous solution
0.5%
55.llRti ̂ TTTO ; 3TO1VCT[W II-Tgng 3(ii)]
Violet)
Neomycin +
Bacitracin
5mg + 500IU/gOintmentP.S.T
5%. Solution or OintmentP,S,TPovidone Iodine
Silver,
Sulphadiazine
1%CreamP,S,T
*
13,3: Antiinflammatory and antipruritic medicines
Route of Administration/
Dosage Form
Category StrengthsMedicines
Betamethasone
Dipropionate
Calamine
0.05%Cream / OintmentP,S,Tt
LotionP,S,T
13.4: Astringent Medicines
Route of Administration/ StrengthsMedicines Category
Dosage Form
Dusting PowderZinc Oxide P,S.T
13.5: Medicines affecting skin differentiation and proiiferation
Route of Administration/
StrengthsCategoryMedicines
Dosage Form
5%SolutionP,S,TCoal Tar
Ointment 0.1-2%TDithranol
■ SolutionP,S,TGlycerin
Salicylic Acid Solution 5%P,S,T
13.6: Scabicides and Pediculicides
Route of Administration/
StrengthsCategoryMedicines
Dosage Form
25 %LotionP,S,TBenzyl benzoate
Added Medicines
5%Cream
Lotion
Permethrin S,T 1%, 5%
Section: 14 -Diagnostic agents
14.1: Ophthalmic medicines
Route of Administration/ StrengthsCategoryMedicines Dosage Form
1%Eye drops
Eye Drops
S,TFluorescein
4%S.TLignocaine
Tropicamide 1%Eye drops
14.2: Radiocontrast media
S,T
Route of Administration/
Dosage Form
StrengthsCategoryMedicines
100% w/v, 250%
SuspensionS,TBarium Sulphate w/v
InjectionS,TCalcium Ipodate
500 mgTabletsS,Tlopanoic Acid
60% w/v (iodine
=280 mg / ml)
Meglumine
lothalamate
InjectionS,T
5-8 g iodine in 100-
250 ml
Meglumine
lotroxate
SolutionS,T
500-600 mg / mlOily, suspensionPropyliodone
Sodium lothalamate
70% w/v{lodine
=420 mg / ml)
InjectionS,T
60% w/v(lodine
cone. *292 mg /
ml), 76% w/v(lodine
cone. =370 mg / ml)
Sodium Meglumine
Diatrizoate
InjectionS.T
f
Section: 15 -Disinfectants and antiseptics
15.1: Antiseptics
Route of Administration/
Dosage Form
StrengthsCategoryMedicines'
SolutionP. S.TAcriflavInr-GIvcerin
56 THE GAZETTE OF INDIA : EXTRAORDINARY [PART U—Sec. 3(ii)]
Benzoin Compound P^T Tincture
20% (cone, for
dilutioni
5% (cone, for dilution)
Cetrimide P,S,T Solution
Chlorhexidine P, S,T Solution
Ethyl Alcohol 70% P, S.T Solution
f
0.5%,Gentian Violet P, S,T Paint
1%
Hydrogen Peroxide P, S,T
P, S,T
Solution 6%
Povidone Iodine Solution 5%, 10%
15.2: Disinfectants
Route of Administration/
Dosage Form
Medicines Category Strengths
Contains not less
than 30 % w/w of.
available chlorine (as
per I.P)
Dilute 34 ml of
formaldehyde
solution with water to
produce 100 ml (As
per I.P)
Bleaching Powder P, S, T Powder
Formaldehyde
Solution • P, S,T Solution
Glutaraldehyde S,T Solution ' 2%
Potassium
P, S,T ‘ Crystals for solutionPermanganate
Section: 16-Diuretics
Route of Administration/
Dosage Form
Medicines Category Strengths
Injection
Tablets
10 mg/ml
40mg
25 mg,
50 mg
Furosemide P,S,T
Hydrochlorothiazide P,S,T Tablets
Mannitol P,S,T Injection 10%, 20%
Spironolactone P,S,T Tablets 25 mg
Section: 17 - Gastrointestinal medicines
17.1: Antacids and other Antiulcer medicines
Route of Administration/
Dosage Form
Medicines Category Strengths
Aluminium Hydroxide
• + Magnesium
Hydroxide
Tablet
Suspension
' P,S,T ■
Omeprazole P,S,T
P.S,T
Capsules 10 mg, 20 mg, 40 mo
25 mg / mlRanitidine Injection
Added Medicines
Pantoprazole Injection
Tablets
40 mg
Famotidine P,S,T- 20 mg
17.2: Antiemetics
Route of Administration/
Dosage Form
Tablets
Syrup
Tablets
Syrup .
Injection
Medicines Category Strengths
Domperidone 10 mg
1 mg / ml
10 mg
5 mg / 5 ml
5 mg / ml
P,S,T
Metoclopramide P,S,T
57
[»tPTlI-W3(ii)]
10 mg, 25 mg
5 mg /5 ml
25 mg / ml
Tablets
Elixir or Syrup
Injection
P.S.TPromethazine
Added Madicines
■».
4mg, 8 mg
2 mg/ml
2mg/rftl
Tablet
Syrup
Injection
Ondansetron S,T
17.3: Antiinflammatory Medicines
I Route of Administration/
Dosage Form
Added Medicines
StrengthsCategoryMedicines
400mg5-Amino salicylic Acid
(5-ASA)
TabletsS,T
17.4: Antispasmodic medicines
Route of Administration/
Dosage Form
StrengthsCategoryMedicines
10 mg
10 mg / ml
TabletsDicyclomine
Hydrochloride
Hyoscine Butyl
. Bromide
P,S,T Injection
Tablets
Injection
10 mg
20 mg / mlP,S,T •
17.5: Laxatives
Route of Administration/
Dosage Form
~ Tablets, Suppository
StrengthsCategoryMedicines
P.S.T
P,S,T
17.6: Medicines used in diarrhorea
17.6.1 Orai dehydration salts
Route of Administration/
Dosage Form
Granules
Bisacodyl
ispaghula
Strengths
CategoryMedicines
Glucose; 13.5 g/L
Sodium chlcric'e 2.6
g/L
Potassium chloriue:
1.5 g/L
Trisodlum citrate
dihydrate+: 2.9 g/L
Powder for dilution in
200ml; 500 ml; .
1000ml. (As per I.P)
Powder for solutionOral Rehydration
Salts
P,S,T
17.6.2 Antidiarrhoeal medicines
Route of Administration/
Dosage Form
Strengths
CategoryMedicines
Medicines added
20 mg/5mlSyrupP,S,T^inc Sulfate■ c
Section: 18 -HennoneS, other endocrine medicines and
contraceptives
• Adrenal hormones and synthetic substitut^
Route of Administration/
Dosage Form
18.1
Category
Strengths
Medicines
0.5mg
4mg/ml
Tablets
S,T InjectionDexamethasone
Hydrocortisone
Sodium Succinate
. 100 mg/ml‘I InjectionP, S,T
L •
'--i
58 THE GAZETTE OF INDIA : EXTRAORDINARY
[Part II—sec. 3(ii)l 'ii
I I. ^Methyl Prednisninno
S,T Injection 40 mg/ ml
Prednisolone 5mo,P, S,T Tablets 10mg,
20m18.2: Andn lens
Medicines Route of Administration/
Dosage Form
Category
Strengths
■»
40mg(as
undecanoate)
I
25mg/ml(as
propionate)
Testosterone Capsules
Injection
P.S.T
16.3: Contraceptives
hormonal Contraceptives
Route of Administration/
Dosage Form
Tablets
18.3.1:
Medicines Category
Strengths
0.03 mg +0.15
Ethinylestradiol +
Levonoroesternl
Ethinylestradiol +
Norethisterone
Hormone Releasing
lU
P,S,T
mg
P,S,T ' Tablets 0.035 mg+1.0 mg
TD Levonorgesterol Releasing
18.3.2: intrauterine devices
Route of Administration/
Dosage Form
lUD
Medicines
lUD containing
Copper
Category
Strengths
P,S,T
18.3.3: Barrier
Route of Administration/
Dosage Form
Medicines Category
StrengthsCondoms P,S,T
18..4: testrogens '
RouU of Administration/
Dosage Form
Medicines Category
Strengths
Ethinylestradiol P,S,T O.OImg
0.05m.q
Tablets
Category Route of Administration/
Dosage Form
Medicines
Strengths
Glibenclamide
” insulin Injection
(Soluble)
Intermediate
Acting(Lente/NPH
InsulinI
P,S,T Tablets 2.5 mg,
5mg
P,S,T Injection 40IU/ml
P.S.T Injection
40IU/ml
Metformin P.S.T
Tablets SOOmg
Added medicinogPremix Insulin'30;70
injection P,S,T
18.5.2 Medicines u.seri
Category
, ,
injection
40IU/ml
^gi!:gglhypoglvcemmRoute of Administration/
Dosage Form
Injection
Medicines
StrengthsGlucagon T
1 mg/mlAdded medicinp^25% Dextro.se
P.S.T
—■ Injection
Igj-Qyolationh^di]^ 100 ml
Medicines Route of Administration/
Dosage Form
Category
Strengths
59^ fqm Il~®ws3(ii)] gn TTTO : 3raiTO
50mg,
100mg
TabletsClomiphene citrate T
18.7 Progestogens
Route of Administration/
Dosage Form
Tablets
i
Medicines Category Strengths
5mg,
lOmg
Medroxy
Progesterone Acetate
Norethisterone
P.S.T
TabletsP,S,T 5mg
18.8 Thyroid and antithyroid medicines
Route of Administration /
Dosage Form
Category StrengthsMedicines
5mg,■P.S.T TabletsCarbimazole 10mg
50pg,Levothyroxine P,S,T Tablets
100
Solution 8 mg / 5 mliodine S,T
Section: 19 Imtnunoloeicak
19.1: Diagnostic agents
Route of Administration/Category StrengthsDrugs Dosage Form
Tuberculin,
Purified Protein
derivative
Injection 1 TU, 5 TUP,S,T
19.2: Sera and immunoglobins
Route of Administration/
Dosage Form StrengthsCategoryDrugs
Anti-D
immunoglobin
(human)
Injection 300 pgS, T
Polyvalent
Antisnake
■ Venom
InjectionP,S,T . 10 ml
Antitetanus
Human'
immunoglobin
Injection 250lU,500 lUP,S,T
I;
* •
Diphtheria
Antitoxin
10,000 lUs, T t \ Injection
Rabies
immunoglobin
’ e mlP,S,T Injection
19.3: Vaccines'i’
19.3.1: For Universal Immunisation
Route of Administration/
. ' Dosage Form StrengthsCategory ;Drugs
*
InjectionP^T -* B.C';G Vaccine
InjectionD.P.T Vaccine P,S,T
Hepatitis‘B
' Vaccine
InjectionP,S,TA >
f ■ ■ I
InjectionP,S,T .IMeasles Vaccine
■ i?Oral.Poliomyelitis
vaccine (i-A)
SolutionP,S,T j
19.3.2: For Specific Group of Individuats
Route of Administration/ Strengths
I
CategoryDrugs Dosage Form
T InjectionP,S,TRabies Vaccine
InjectionP.S.TTetanus Toxoid
60 THE GAZETTE OF INDIA : EXTRAORDINARY [PARTlI-^SEC.-3(ii)]0
A. •Section; 20 - Muscle Relaxants (Peripherally acting) and
Cholinesterase Inhibitors
T-i
'1
Route of Administration/
Dosage Form
T
Drugs Category Strengths
Atracurium
besylate S,T Injection 10 mg Ami, ■
Tablets,'
Injection
'♦ ■Neostigmine 15 mg,
0.5mq/ml '
S,T
Tablets,
Injection
Pyridostigmine 60 mg,
1 mg/ml
S,T
Succinyl choline
chloride S,T Injection 50 rng/ml
Added drugs
• Vecuronium P,S,T Injection 2 mg/ml
Section; 21 - Ophthalmological Preparations
21.1: Anti-infective agents
Route of Administration/ Dosage
Form
Medicines Category Strengths
Chlorampheni
■■P,S,T Drops/Ointmentcol 0.4%, .1%
Ciprofloxacin
Hydrochloride P,S,T Drops/Ointment 0.3%
Gentamicin P,S,T
P,S,T
Drops
Drops
0.3%Miconazole
Povidone
Iodine
1%.
S,T . Drops 0.6%
Sulphaceta
mide
Sodium
P,S,T Drops 10%,20%
21.2: Antiinflammaory agents
Route of Administration/ Dosage
Form
Medicines Category Strengths '
Prednisolone
Acetate P,S,T ■ 4,Drops 0.1% •'
Prednisolone
Sodium
Phosphate
K.P,S,T Drops 1%
21.3: Local Anaesthetics
Route of Administration/ Dosage
^rm
Medicines Category Strengths
Tetracaine
Hydrochloride P,S.T Drops 0.5%
21.4: MIotics and Antiqlucoma medlclnna
Category Route of Administration/ Dosage
Form
Medicines
Strengths
Acetazolamide S,T Tablets 250 mg
0.25%,
Betaxolol
Hydrochloride T Drops
0..5%
Pilocarpine S,T 2%,Drops y
4%'Timolol
P, S.T 0.25%,Maleate Drops
0.5%.21.5: Mydriatics
Route of Administration/ Dosage
Fofm
Medicines Cat^ory
Strengths
Atropine
Sulphate
HomatfODine
Phenylephrine
P.S.T Drops/Ointment 1%.
■/' Drops 2%.>P.8,T L
Drops 5%:,;
T'
6
l:«
61[WT Il-^3(ii)] ma an Traaa : arai’wn
/
21.6; Ophthalmic Surgical Aids
Route of Administration/ Dosage
Form
Medicines Category Strengths
Methyl
Cellulose
'i
T Injection' 2%
Section: 22 - Oxytocics and Antioxytocics
22.1: Oxytocics
Route of Administration/
Dosage Form
Medicines Category Strengths
Methyl
Ergometrine
Tablets
Injection
0.125mg
0.2mg/ml
P,S,T
Mifepristone T Tablets 200mg1 >
5IU/ml,
lOlU/ml
Oxytocin S,T Injection
Added medicines
Misoprostol T Tablets lOOug
22.2: Antioxytocics
Route of Administration/
StrengthsMedicines Category
Dosage Form
Terbutaline
Sulphate
Tablets
! Injection
2.5 mg.
0.5 mg/ml
S,T
Added Medicines
Tablets 10 mgS,TNifedipine
Betamethasone Injection 4 mg/mlP,S,T
Section: 23 - Peritoneal Dialysis Solution-
Route of Administration/
Dosage Form
StrengthsCategoryMedicines
40f approximate
composition
Intraperitoneal
Dialysis Solution-
T
Section: 24 - Psychotherapeutic Medicines -
♦ 24.1: Medicines used in Psychotic Disorders
Route of Administration/ StrengthsMedicines Category
Dosage Form
25 nig, 50mg, lOOmg
25mg/5ml
25mg/ml
Smg/ml
Tablets
Syrup
Injection
Chlorpromazine
hydrochloride
i P.S.T
InjectionS,THaloperidol
Added medicines
5mq,10mgTabletsTOlanzapine
24.2: Medicines used in mood disorders
24.2.1: Medicines used in Depressive disorders
Route of Administration/
Dosage Form
StrengthsCategoryMedicines
25 mgTabletsP*SiT
PJX-
Amitriptyline
20 mgCapsulesFluoxetine
62 THE GAZETTE OF INDIA : EXTRAORDINARY [Part ll—Sec. 3(ii)]
hydrochloride
Imipramine P.S.T Tablets 25 mg, 75 mg
24.2.2: Medicines used in Bipolar disorders
Route of Administration/
Dosage Form
Medicines Category Strengths
i
Lithium
Carbonate
T Tablets 300 mg
Added Medicines
200 mg,
500mg
Sodium,
Valproate
TabletsP.S.T
24.3: Medicines used for Generalized Anxiety and Sleep Disorders
Route of Administration/
Dosage Form
Tablets
Category Str
0.2p.s,r
Medicines engths
5 mg,
0.5 mg
Alprazolam
2 mg,
5mg
24.4: Medicines used for obsessive compulsive disorders and panic attacks
Route of Administration/
Dosage Form
P,S,T Tabiets
Category Strength
Diazepam
Medicines s
Added Medicines
Fluoxetine
hydrochloride P.S.T Capsules 20 mg
Section: 25 - Medicines acting on the respiratory tract
25.1: Antiasthmatic medicines
Route of Administration/
Dosage Form
Medicines StrengthCategory
50 pg,
250pg/do
. Beclomethasone Dipropionate P,S,T Irihaiation
se
Hydrocortisone
sodium succinate
100 mg,
200mg,
400 mg
2mg, 4mg
2mg/5ml
lOOpg/do
P,S,T Injection
Tablets
Syrup
Inhalation
Saibutamol
sulphate P,S,T
se
Added Medicines
Ipratropium
bromide ■ 20pg/met
ered dose
P,S,T inhalation
25.2: Antitussives
Route of Administration/
Dosage Form
Medicines StrengthCategory
s
lOmgCodeine phosphate Tabiets
Syrup
S,T 15mg/
5ml
Dextromethorphan P,S,T Tabiets 30mg
Section: 26 - Solutions correcting water, electrolyte and acid-base
disturbances i
26.1: Oral
Route of Administration/
Dosage Form
Medicines Category
Strengths
Oral
Rehydration P, S, T Powder for Solution As per IPSalts
26.2: Parenteral
Route of Administration/
Dosage Form
Medicines Category
Strengths
5% isotonic, 10%
15%.
Glucose P, S.T Injection
Glucose with
sodium chloride P, S, T Injection 5% + 0.9%
63
TO ̂ Wra : TOVIFI[SPlIl-T3nS3(ii)]
^<1
0.9%Injection -P, S, TNormal Saline
InjectionS,TN/2 Saline
InjectionS.TN/5 Saline
Potassium
Chloride
11.2% Sol.InjectionP.S.T
As per IPInjection .P, S,TRinger Lactate
i Sodium As per IPInjectionP, S,T
Bicarbonate
26.3: Miscellaneous
Route of Administration/
Dosage Form
StrengthsCategoryMedicines
Water for
Injection
2 ml, 5 ml, 10 mlInjectionP, S,T
Section: 27 - Vitamins and Minerals
Route of Administration/
Dosage Form
StrengthsCategoryMedicines
100 mg, 500 mgTabletsP.S,TAscorbic Acid
Calcium
carbonate
250 mg, 500 mgTabietsP,S,T
liiluitivitamins (As per
Scheduie V of Drugs and
Cosmetics Rules)
TabletsP,S,T
50 mgTabletsP,S,T
P,S,T
Nicotinamide
25 mgTabietsPyridoxine
5 mg. TabietsP,S,TRiboflavin
100 mgTabietsP,S,TThiamine
5000lU,
50000lU,100000Tabiets
CapsuiesP,S,T lU,Vitamin A
50000 lU/ml
0,25 mg, 1 mg
Injection
CapsuiesP.S,TVitamin D (Erqocalciferoi)
Added Medicines
lOOmg/ml in 10 ml
ampouleCalcium
gluconate
InjectionP,S,T
SCHEDULE-II
FORM- I
APPLICATION FOR PRICE FIXATION / REVISION OF A NEW DRUG FORMULATION
RELATED TO NLEM FORMULATION
(See paragraphs 2(u),5,7,8,9,15)
PROFORMA FOR
Name of the formuiation:
iVame and address of the manufacturer/importer:
Name of the Marketing Company, if any:
labei claimed and approved by Drug Control Authorities:
Drugs Control Authority Permission Number and Date (copy to be enclosed).
Date of commencement of production / import:
Type of formulation (Tablets/Capsules/ Syrup/ Injection/ Ointment/
Size of packs (lO's/ lOO's/ 1 ml/ 2 ml/ 10 ml/ 5 gms/ 10 gms etc.)
Therapeutic category/ use of the formulation.
The Retail Price claimed for approval
Reason for submission of application for price fixation / revision.
Any other information relevant to product and its process l
Composition as per
Powder
of manufacturing/
1.
2.
3.
4.
5.
6.
etc.):
7.
S;
I
9.
10.
11.
packaging/ distribution.
12.
64
— • extraordinary
The informaUon furnished above is correct and true to the
Place:
best of my knowledg
[Part II—Sec. 3fii)1
e and belief.
Authorized Signatory:
Name:
Designation:
l><^
Date:
.?
SCHEDULE-II
FORM - II
PROFORMA FOR SUBMISSION OF revised-prices for scheduled FORMUUTIONS
(See paragraph 16)
1.
Name and address of the marketing company, if any.2.
SI. No. Name of the
Product
(Formulation
and its
dosage
forms)
Composition
of scheduled
formulation/
new drug
Pack WPI Price to retailer
.. (incl. of E.D.)
Maximum
Retail Price
(incl. of
E.D:&Taxes)
(Rs.)
Ceiling
Price
(Notified)
Effec-Size change
w.r.t.
preced
ing Year
tive
(Rs.)
Batch
(Rs.) No.
and
date
Pre-
Revised
Revi- Pre-
Revi-
Revi-
sed sed
sed(1) (2) (3) (4) (5) (6) (7) (8) (9)Scheduled Formulations
Own Manufactured Formulations
(Id) (11)
Purchased/Imported Formulations
Notes;; In case of purchased formulation.
The information furnished above r
Place:
name of the manufacturer shaii be indicated.
» correa and true to the best of nty knowledge and belief.
Authorised Signatory:
Name:
Designation:
Date:
SCHEDULE-II
form - III
proforma for quarterly return
[See paragraphs 21(1)]
and sale of
1. Name and address of the
2. Name and address of i
3. Details of production/import
manufacturer/importer ;
marketing company, if any :
and sale for the Quarter of a Year:
1
65
ma an ima : armwa[«?m ll-73Trg 3(ii)]
TABLE-A
Unit(No/kg/Ltr)Dosage FormComposition/Strength ,Name of the Scheduled
Formulation
(4)(3)(2)(1)
Production/Import
Level
Current Year
€
Previous Year TIT
3^ Quarter 4"' Quarter2^ QuartersT
r' Quarter
ill161
Domestic Sale
Current Year
2"° Quarter~
Previous Year 4"’ Quarter3"'’ Quarter1°' Quarter
1141(13)(12)(11)IM
TABLE-B
Installed CapacityUnit(Kg/Ltr)
Name of the Bulk Drug/API used in
Scheduled Formulation
(3)(2)
(1)
Production/Import
Level
Current Year
2”° Quarter
Previous.Year r Quarter3^°. Quarter
V Quarter
(8)(7)(6)(5)(4).
Domestic'Sale
Current Year
2”° Quarter ~
Previous Year 4'" Quarter3"* Quarter1^'Quarter
(13)(12)(11)(10)(9)
belief.
Authorised Signatory:
Name:
Designation:
Place:
Date:
t
SCHEDULE-II
FORM ■ IV
proforma
[See paragraphs 21(2)1
1. Name of the formulation:
66 THU GAZETTE OF INDIA : EXTRAORDINARY [Part 11—sec. 3(ii)]
2. Name and address of the manufacturer/importer;
3. Name of the Marketing Company, if any:
4. Composition as per label claimed and approved by Drug Control Authorities:
5. Drugs Control Authority Permission Number and Date (copy to be enclosed):
6. Celling Price and date of notification;
7. Existing maximum retail price (MRP) and its effective date:
8. Therapeutic category as per NLEM:
9. Date of commencement of production / import
10. Proposed date of discontinuation;
V?
11. Reasons for discontinuation of production / import;
12. Year-wise Production/Import during the last 5 years including current year
13. Year-wise sale during the last 5 years including current year
15. Any other information relevant to discontinuation of scheduled formulation:
Authorized Signatory:
Name:
Place:
Date:
Designation:
SCHEDULE-II
FORM-V
PROFORMA FOR PRICE LIST
[See paragraphs 2(x),24,25,26]
1. Name and address of the manufacturer / importer / distributor
2. Name and address of the marketing company, if any.
TABLE-A
SI. No. Name of the Product
(Formulation and its
dosage forms)
Composition
approved by Drug
Control
Authorities
Pack Size Price to
retailer
(incl. of
ED.)(Rs.)
Maximum Retail
Price (incl. of
E.D.&Taxes) (Rs.)
9
(1) (2) (3) (4) (5) (6)Scheduled Formulations
Own Manufactured
Formulations
Purchased/Imported
Formulations
67
TABLE-B
Maximum Retail
Price (incl. of
E.D.&Taxes) (Rs.)
Price to
retailer
(incl. of
E.D.) (Rs.)
Pack SizeComposition
approved by Drug
Control
■Authorities
Name of the Product
(Formulation and its
dosage forms)
SI. No.
(6)(5)(4)(3)(2)(1)
Non-Scheduled Formulations
Own Manufactured
Formulations
Purchased/Imported
Formulations
In case of purchased formulation, name of the manufacturer shall be indicated.
The information furnished above is correct and true to the best of my knowledge and belief.
Notes:-
Authorised Signatory:
Name:
Designation:
Place:
Date:
t
Printed by the Manager. Government of Ind.a Ring Road, Mayjur, New Delhi-110064
and Published by the Controller of Pubheations, Delhi-110054.